Patents

Search All Patents:



  This Patent May Be For Sale or Lease. Contact Us

  Is This Your Patent? Claim This Patent Now.







Register or Login To Download This Patent As A PDF




United States Patent Application 20110263499
Kind Code A1
Beyer, JR.; Wayne F. ;   et al. October 27, 2011

IFBM'S TO PROMOTE THE SPECIFIC ATTACHMENT OF TARGET ANALYTES TO THE SURFACE OF ORTHOPEDIC IMPLANTS

Abstract

The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related material ("implant module") and at least one binding module that selectively binds to a target analyte or that is designed to have a desired effect ("analyte module"). The modules are connected by a linker. In some embodiments, the IFBM coating acts to promote the recognition and attachment of target analytes to surface of the device. The IFBM coating improves the performance of implanted medical devices, for example, by promoting osteointegration of the implant.


Inventors: Beyer, JR.; Wayne F.; (Bahama, NC) ; Hyde-DeRuyscher; Robin; (Chapel Hill, NC) ; Hamilton; Paul T.; (Cary, NC) ; Benson; Ray Edward; (Durham, NC)
Serial No.: 174884
Series Code: 13
Filed: July 1, 2011

Current U.S. Class: 514/8.8; 435/226; 530/324
Class at Publication: 514/8.8; 530/324; 435/226
International Class: A61K 38/18 20060101 A61K038/18; A61P 19/00 20060101 A61P019/00; C12N 9/64 20060101 C12N009/64; C07K 14/51 20060101 C07K014/51


Claims



1-19. (canceled)

20. An implant comprising a polypeptide that binds to a bone morphogenetic protein, wherein the polypeptide is selected from the group consisting of: (i) the polypeptide set forth in any one of SEQ ID NOs: 27 or 73; (ii) the polypeptide set forth in any one of SEQ ID NOs: 11-24, 44-72, or 74; (iii) the polypeptide having at least 70% identity to any one of the polypeptides set forth in SEQ ID NOs: 11-24, 44-55, 57-72, or 74; (iv) the polypeptide having at least 75% identity to any one of the polypeptides set forth in SEQ ID NOs: 11-24, 44-72, or 74; and (v) the polypeptide that is a conservatively substituted variant of any one of the polypeptides set forth in SEQ ID NOs: 11-24, 44-72, or 74.

21. The implant of claim 20, wherein the polypeptide is set forth in any one of SEQ ID NOs: 27 or 73 and the polypeptide consists of no more than 40 amino acids in length.

22. The implant of claim 20, wherein the polypeptide is set forth in any one of SEQ ID NOs: 27 or 73 and the polypeptide consists of no more than 30 amino acids in length.

23. The implant of claim 20, wherein the polypeptide is set forth in any one of SEQ ID NOs: 27 or 73 and the polypeptide consists of no more than 20 amino acids in length.

24. The implant of claim 20, wherein the polypeptide is set forth in any one of SEQ ID NOs: 27 or 73 and the polypeptide consists of no more than 17 amino acids in length.

25. The implant of claim 20, wherein the polypeptide is set forth in any one of SEQ ID NOs: 27 or 73 and the polypeptide consists of no more than 10 amino acids in length.

26. The implant of claim 20, wherein the polypeptide is set forth in any one of SEQ ID NOs: 27 or 73 and the polypeptide consists of no more than 7 amino acids in length.

27. The implant of claim 20, wherein the bone morphogenetic protein is bone morphogenetic protein-2.

28. A method for promoting bone formation, the method comprising placing a polypeptide that binds to a bone morphogenetic protein (BMP) at a site for bone formation, wherein the polypeptide binds and presents the BMP to promote the bone formation, and wherein the polypeptide is selected from the group consisting of: (i) the polypeptide set forth in any one of SEQ ID NOs: 27 or 73; (ii) the polypeptide set forth in any one of SEQ ID NOs: 11-24, 44-72, or 74; (iii) the polypeptide having at least 70% identity to any one of the polypeptides set forth in SEQ ID NOs: 11-24, 44-55, 57-72, or 74; (iv) the polypeptide having at least 75% identity to any one of the polypeptides set forth in SEQ ID NOs: 11-24, 44-72, or 74; and (v) the polypeptide that is a conservatively substituted variant of any one of the polypeptides set forth in SEQ ID NOs: 11-24, 44-72, or 74.

29. The method of claim 28, wherein the bone morphogenetic protein is bone morphogenetic protein-2.

30. A method for promoting osteointegration, and/or accelerating healing, and/or reducing inflammation at a site of an implant, the method comprising localizing a polypeptide that binds to a bone morphogenetic protein (BMP) at the site of the implant, wherein the polypeptide binds and presents the BMP for the promoted osteointegration, and/or accelerated healing, and/or reduced inflammation, and wherein the polypeptide is selected from the group consisting of: (i) the polypeptide set forth in any one of SEQ ID NOs: 27 or 73; (ii) the polypeptide set forth in any one of SEQ ID NOs: 11-24, 44-72, or 74; (iii) the polypeptide having at least 70% identity to any one of the polypeptides set forth in SEQ ID NOs: 11-24, 44-55, 57-72, or 74; (iv) the polypeptide having at least 75% identity to any one of the polypeptides set forth in SEQ ID NOs: 11-24, 44-72, or 74; and (v) the polypeptide that is a conservatively substituted variant of any one of the polypeptides set forth in SEQ ID NOs: 11-24, 44-72, or 74.

31. The method of claim 30, wherein the bone morphogenetic protein is bone morphogenetic protein-2.

32. A method for binding bone morphogenetic protein (BMP) in vitro, the method comprising incubating a BMP with a polypeptide that binds to the BMP under conditions suitable for binding, wherein the polypeptide is selected from the group consisting of: (i) the polypeptide set forth in any one of SEQ ID NOs: 27 or 73; (ii) the polypeptide set forth in any one of SEQ ID NOs: 11-24, 44-72, or 74; (iii) the polypeptide having at least 70% identity to any one of the polypeptides set forth in SEQ ID NOs: 11-24, 44-55, 57-72, or 74; (iv) the polypeptide having at least 75% identity to any one of the polypeptides set forth in SEQ ID NOs: 11-24, 44-72, or 74; and (v) the polypeptide that is a conservatively substituted variant of any one of the polypeptides set forth in SEQ ID NOs: 11-24, 44-72, or 74.

33. The method of claim 32, wherein the bone morphogenetic protein is bone morphogenetic protein-2.
Description



CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a continuation application of pending U.S. Non-provisional application Ser. No. 12/871,194, filed on Aug. 30, 2010, which is a divisional application of U.S. Non-provisional application Ser. No. 12/488,183, filed on Jun. 19, 2009, now U.S. Pat. No. 7,812,119, which is a divisional application of U.S. Non-provisional application Ser. No. 11/152,974, filed on Jun. 15, 2005, now U.S. Pat. No. 7,572,766, which claims priority to U.S. Provisional Application No. 60/580,019, filed Jun. 16, 2004; U.S. Provisional Application No. 60/651,338, filed Feb. 9, 2005; and U.S. Provisional Application No. 60/651,747, filed Feb. 10, 2005; each of which is hereby incorporated in its entirety by reference herein.

FIELD OF THE INVENTION

[0002] The present invention provides materials and methods for coating surfaces of medical devices with interfacial biomaterials that promote the specific recognition and attachment of the target analyte to the surface of the device.

BACKGROUND OF THE INVENTION

[0003] Orthopedic implants are used for a variety of joint replacements and to promote bone repair in humans and animals. According to medical industry analysts, there are now over 800,000 hip and knee joint replacements performed in human patients each year in the U.S. In addition, hundreds of thousands of human patients undergo surgical procedures in which orthopedic implants are used, for example, to treat various types of bone fractures or to relieve severe back pain.

[0004] With all of these procedures, there is a need for controlled, directed, rapid healing. Individuals undergoing joint replacement often experience uncomplicated healing and restoration of function. Unfortunately, there is a high rate of complications, including "late failures." The revision surgery rate for human total joint replacement varies between 10 to 20% (Malchau et al. (2002) "Prognosis of total hip replacement: Update of results and risk-ratio analysis for revision and re-revision from the Swedish National Hip Arthroplasty Registry, 1979-2000," scientific exhibition at the 69th Annual Meeting of the American Academy of Orthopaedic Surgeons, Dallas, Tex., Feb. 13-17, 2002; Fitzpatrick et al. (1998) Health Technol. Assess. 2:1-64; Mahomed et al. (2003) J. Bone Joint Surg. Am. 85-A:27-32)). The majority of these revision surgeries are made necessary by failure at the implant-bone interface.

[0005] Orthopedic implants are made of materials which are relatively inert ("alloplastic" materials), typically metallic, ceramic, or plastic materials. Previous approaches to improve the outcomes of orthopedic implant surgeries have mainly focused on physical changes to the implant surface that result in increased bone formation. These approaches include using implants with porous metallic surfaces to promote bone ingrowth and spraying implants with hydroxyapatite plasma. Approaches using dental implants have also included the use of topographically-enhanced titanium surfaces in which surface roughness is imparted by a method such as grit blasting, acid etching, or oxidation. While these techniques have improved the outcomes of orthopedic implant surgeries, there is still considerable room for further improvement.

[0006] Tissue response to an alloplastic material is known to be influenced by cell adhesion to the material's surface, and much research has been directed to improving cell adhesion to alloplastic materials. Cell adhesion between cells in vivo is known to be controlled primarily by the binding of short, exposed protein domains in the extracellular matrix to cell surface receptors (LeBaron & Athanasiou (2000) Tissue Eng. 6: 85-103; Yamada (1997) Matrix Biol. 16: 137-141). Notably, a class of receptors known as integrins has been implicated in cell adhesion to implant surfaces. Integrins and their target ligands have been shown to stimulate osteoblast adhesion and proliferation as well as bone formation (see, e.g., Kantlehner et al. (2000) ChemBioChem 1: 107-114; Sarmento et al. (2004) J. Biomed. Mater. Res. 69A: 351-358; Hayashibara et al. (2004) J. Bone Mineral Res. 19: 455-462. Integrins may be useful in targeting cell adhesion to implants and in this manner may improve integration of implants into adjacent bone.

[0007] Other research has shown that the local expression of growth factors and cytokines can enhance tissue reactions at alloplastic implant surfaces. For example, Cole et. al. ((1997) Clin. Orthop. 345: 219-228) have shown that growth factors can promote the integration of an implant into adjacent bone ("osteointegration") as well as increase the rate of bone formation next to the implant surface. See also U.S. Pat. No. 5,344,654.

[0008] Growth factors that stimulate new bone production ("osteoinductive proteins") include, but are not limited to, platelet-derived growth factor (PDGF), insulin-like growth factors 1 and 2 (IGF-1 and IGF-2), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), transforming growth factor (TGF-.beta.), bone morphogenic proteins (BMP), and associated family members.

[0009] The most effective osteoinductive proteins are the bone morphogenetic proteins (BMPs). The BMPs are members of the TGF-.beta. superfamily that share a set of conserved cysteine residues and a high level of sequence identity overall. Over 15 different BMPs have been identified, and most BMPs stimulate the cascade of events that lead to new bone formation (see U.S. Pat. Nos. 5,013,649; 5,635,373; 5,652,118; and 5,714,589; also reviewed by Reddi and Cunningham (1993) J. Bone Miner. Res. 8 Supp. 2: S499-S502; Issack and DiCesare (2003) Am. J. Orthop. 32: 429-436; and Sykaras & Opperman (2003) J. Oral Sci. 45: 57-73). This cascade of events that leads to new bone formation includes the migration of mesenchymal stem cells, the deposition of osteoconductive matrix, the proliferation of osteoprogenitor cells, and the differentiation of progenitor cells into bone-producing cells. Much research has been directed to the use of BMPs on or near implants in order to promote osteointegration of the implants (see, e.g.: Friedlander et al. (2001) J. Bone Joint Surg. Am. 83-A Suppl. 1 (Pt. 2): S151-58; Einhorn (2003) J. Bone Joint Surg. Am. 85-A Suppl. 3: 82-88; Burkus et al. (2002) J. Spinal Disord. Tech. 15(5): 337-49). However, one of the critical issues that remains unresolved is the method of grafting or immobilizing an active BMP or other active biomolecule onto the surface of an implant.

[0010] It has been shown that the presentation of BMPs is critical for producing desired bone formation next to an implant device. Approaches to improving implants have been modeled in view of the natural process of bone formation. In human bone, collagen serves both as a scaffold for bone formation and as a natural carrier for BMPs. Demineralized bone has been used successfully as a bone graft material; the main components of demineralized bone are collagen and BMPs (see U.S. Pat. No. 5,236,456). Many matrix systems have been developed that are designed to encourage bone formation by steadily releasing growth factors and other bioactive molecules as the matrix degrades. The efficiency of BMP release from polymer matrixes depends on matrix characteristics such as the affinity of BMP for the matrix, resorbtion rate, density, and pore size. Materials used in such matrix systems include organic polymers which readily hydrolyze in the body into inert monomers. Such organic polymers include polylactides, polyglycolides, polyanhydrides, and polyorthoesters (see U.S. Pat. Nos. 4,563,489; 5,629,009; and 4,526,909). Other materials described as being useful in BMP-containing matrices include polylactic and polyglycolic acid copolymers, alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer, and poly (vinyl alcohol) (see U.S. Pat. No. 5,597,897). Natural matrix proteins have also been used to deliver BMPs to bone areas; these natural proteins include collagen, glycosaminoglycans, and hyaluronic acid, which are enzymatically digested in the body (see U.S. Pat. Nos. 4,394,320; 4,472,840; 5,366,509; 5,606,019; 5,645,591; and 5,683,459).

[0011] Even with the use of a polymer matrix to retain BMP at the site of repair, it has been found that supraphysiological levels of BMP are required in order to promote healing due to the rapid diffusion of growth factors out of the matrix. For example, with a collagen sponge delivery system, only 50% of the BMP added to the sponge is retained after two days (Geiger et al. (2003) Adv. Drug Del. Rev. 55: 1613-1629). The high initial dose of BMPs required to maintain physiological levels of BMP for the necessary period of time makes BMP treatment more expensive and may lead to detrimental side effects such as ectopic bone formation or allergic reactions, or the formation of neutralizing antibodies.

[0012] Similar problems exist with other implants such as tendon and ligament replacements, skin replacements, vascular prostheses, heart pacemakers, artificial heart valves, breast implants, penile implants, stents, catheters, shunts, nerve growth guides, intraocular lenses, wound dressings, and tissue sealants. As with orthopedic implants, surgery involving these implants often gives rise to similar problems with the slow healing of wounds and, where desirable, improper integration of the implant into surrounding tissue.

[0013] Thus, there remains a need for the development of cost-effective methods for grafting active biomolecules to the surface of materials used as implants or in conjunction with implants in order to promote post-surgical healing and, where desirable, integration of the implant into surrounding tissues, such as, for example, adjacent bone.

SUMMARY OF THE INVENTION

[0014] The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related material ("implant module") and at least one binding module that binds to a target analyte or that is designed to have a desired effect ("analyte module"). The modules are connected by a linker. In some embodiments, the IFBM coating acts to promote the recognition and attachment of target analytes to surface of the device. The IFBM coating improves the performance of implanted medical devices by promoting osteointegration of the implant, accelerating healing, and/or reducing inflammation at the site of the implant.

BRIEF DESCRIPTION OF THE DRAWINGS

[0015] FIG. 1 shows a comparison of the binding of phage that display representative titanium-binding peptides to titanium beads (see Example 1). Signal of assay for binding to titanium beads (vertical axis) is shown for various phage (horizontal axis).

[0016] FIG. 2 shows a comparison of the binding of peptides with a C-terminal biotin residue to titanium (see Example 1). Absorbance (vertical axis) is shown as a function of peptide concentration (.mu.M, on the horizontal axis).

[0017] FIG. 3 shows a comparison of binding to titanium of two peptides (see Example 2). A405 nm signal (vertical axis) is shown as a function of peptide concentration (.mu.M, on the horizontal axis). The lines shown on the graph from top to bottom join data points for peptides AFF6007 and AFF6010, respectively.

[0018] FIG. 4 shows a comparison of binding of various peptides to BMP-2 (see Example 3). Signal (rate AP) is shown for various peptides (identified on the horizontal axis).

[0019] FIG. 5 shows the effect of BMP on the binding of IFBMs to a collagen sponge (see Example 4). Signal (vertical axis) is shown as a function of BMP concentration in nM (horizontal axis).

[0020] FIGS. 6A, 6B, 6C, and 6D show the results of an experiment described in Example 4 which demonstrates that the binding of BMP to collagen via an IFBM is dependent on both the amount of BMP put into the sponge and also on the amount of IFBM present. Absorbance (vertical axis) is shown as a function of BMP concentration (horizontal axis).

[0021] FIG. 7 shows the results of an analysis of all the peptide sequences from Tables 3 and 4 that bind BMP-2 and contain Motif 1 (see Example 3). The figure shows for each analyzed position the number of times each amino acid was found in that position in the peptide sequences analyzed; for example, "G2" in position 1 means that Glycine was found two times in that position.

[0022] FIG. 8 shows the oligonucleotide cassette which was designed to express a peptide (SEQ ID NO: 74) containing the core binding Motif 1a in the context of a peptide sequence which also contained consensus residues identified for other positions in the sequence (see Example 3). The nucleotide sequences shown in the figure are also set forth in SEQ ID NO: 75 and SEQ ID NO: 76.

[0023] FIG. 9 shows results from a conventional ELISA performed to evaluate the relative affinity of BMP binding peptides (see Example 3). The signal from the ELISA (A405 nm reading) is presented on the vertical axis as a function of microliters of phage on the horizontal axis. At the data points corresponding to 0.10 microliters of phage, the lines shown on the graph from top to bottom join data points for: APO2-61, APO2-40, APO2-41, APO2-26, APO2-35, APO2-59, APO2-44, mAEK, and the no-phage control, respectively.

[0024] FIG. 10 shows the results of an analysis of all the peptide sequences from Tables 3 and 5 that bind BMP-2 and contain Motif 2. The figure shows for each analyzed position the number of times each amino acid was found in that position in the peptide sequences analyzed; for example, "G7" in position 1 means that Glycine was found seven times in that position. Also shown are a consensus sequence derived from an alignment of the peptides from Tables 3 and 5 that contain Motif 2 (SEQ ID NO: 93). This sequence represents the predominant amino acid found at each position after all the peptides are aligned. Among the sequences examined, the most conserved amino acids form a core binding motif designated "Motif 2a" (SEQ ID NO: 94).

[0025] FIG. 11 shows representative results from an alternate assay for BMP-binding activity in which binding occurs in the solution phase (see Example 3). Absorbance at 405 nm (vertical axis) is shown as a function of picomoles of BMP (horizontal axis). These results were used to calculate the affinity of each BMP-binding peptide for BMP-2 (see Table 6). At the data point corresponding to one picomole of BMP, the lines shown on the graph from top to bottom join data points for: 2006, 2007, 2008, 2009, 2011, and 2012, respectively.

[0026] FIG. 12 shows results from an assay in which several peptides were tested for their ability to bind to BMP-2, BMP-4, and BMP-7 (see Example 3). The 2007 and 2011 peptides were originally identified as BMP-2 binding peptides, while the 9001 peptide was originally identified as binding to an unrelated target.

DETAILED DESCRIPTION OF THE INVENTION

[0027] The present invention provides an improved coating for surfaces of medical devices to promote the attachment of peptides, proteins, drugs, or cells to the device. The coating is an interfacial biomaterial (IFBM) that comprises multiple binding modules that are linked. The IFBM comprises at least one binding module which binds to the surface of the implant ("implant module") and at least one binding module that binds to a target analyte or has a desired effect ("analyte module"). Exemplary binding modules comprise the peptide sequences provided, for example, in the sequence listing (SEQ ID NOs: 1-74 and 77-558). The modules are connected by a linker In some embodiments, the binding of the binding module of an IFBM to the surface of an implant is non-covalent. Similarly, in some embodiments, the binding of an analyte module to a target analyte is non-covalent. According to one embodiment, the implant module and the analyte module comprise two separate peptide molecules such that the implant module binds to an implant material and the analyte module binds specifically to a growth factor or cell. In some embodiments, the implant module and the analyte module are linked by a central macromolecule. These binding modules typically bind non-covalently to the implant material or target analyte, respectively. In embodiments where the analyte module does not bind to a target analyte but rather has a desired effect, the analyte module may, for example, simulate the action of a growth factor by acting to recruit cells to the location of the implant. The IFBM selection method and structure are described in U.S. patent application Ser. No. 10/300,694, filed Nov. 20, 2002 and published on Oct. 2, 2003 as publication number 20030185870, which is herein incorporated by reference.

[0028] By "binds specifically" or "specific binding" is intended that the implant module or analyte module binds to a selected implant material or to a selected analyte. In some embodiments, a module that binds specifically to a particular implant material or analyte binds to that material or analyte at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, or a higher percentage more than the module binds to an appropriate control such as, for example, a different material that is used in implants, a material that is not used in implants, or a protein typically used for such purposes such as bovine serum albumin. By "analyte" is intended any substance or moiety that improves osteointegration of an implant or promotes or accelerates healing of the surrounding tissues following implant surgery. Suitable analytes which are binding targets for analyte modules include, but are not limited to, growth factors such as bone morphogenic proteins (BMPs, such as, for example, BMP-7 and BMP-2), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), transforming growth factor-.beta. (TGF-.beta.), insulin growth factor-1 (IGF-1), insulin growth factor-2 (IGF-2), fibroblast growth factor (FGF), nerve growth factor (NGF), and placental growth factor. Suitable analytes also include hormones, enzymes, cytokines, and other bioactive substances or moieties which are useful in obtaining the goals of the invention; that is, to promote osteointegration of an implant and/or to improve healing of surrounding tissues following implant surgery. Suitable analytes also include cells, for example, osteoblasts, chondrocytes, stem cells, progenitor cells, platelets, and other cells which perform roles in osteointegration and healing. In some embodiments, analyte modules can comprise peptide sequences that bind cells or have bioactivity through binding to cells or receptors such as, for example, the peptide sequences RGD, YIGSR, and IKVAV, which are known in the art to have particular biological activities. See, e.g., Hersel et al. (2003) Biomaterials 24: 4385-4415; Grant et al. (1990) Ann. N.Y. Acad. Sci. 588: 61-72; Hosokawa et al. (1999) Dev. Growth Differ. 41: 207-216. In some embodiments, analyte modules comprise peptide sequences which bind to and/or mimic the effect of BMP-2, such as the exemplary sequences set forth in SEQ ID NOs: 11-28, 44-74, or 77-94. An analyte module that binds to cells can comprise a peptide that comprises a general cell attachment sequence that binds to many different cell types, or it can comprise a peptide that binds to a specific cell type such as an osteoblast, a chondrocyte, an osteoprogenitor cell, or a stem cell.

[0029] The term "implant" generally refers to a structure that is introduced into a human or animal body to restore a function of a damaged tissue or to provide a new function. An implant device can be created using any biocompatible material to which binding agents can specifically bind as disclosed herein. Representative implants include but are not limited to: hip endoprostheses, artificial joints, jaw or facial implants, tendon and ligament replacements, skin replacements, bone replacements and artificial bone screws, bone graft devices, vascular prostheses, heart pacemakers, artificial heart valves, breast implants, penile implants, stents, catheters, shunts, nerve growth guides, intraocular lenses, wound dressings, and tissue sealants. Implants are made of a variety of materials that are known in the art and include but are not limited to: a polymer or a mixture of polymers including, for example, polylactic acid, polyglycolic acid, polylactic acid-polyglycolic acid copolymers, polyanhidrides, polyorthoesters, polystyrene, polycarbonate, nylon, PVC, collagen (including, for example, processed collagen such as cross-linked collagen), glycosaminoglycans, hyaluronic acid, alginate, silk, fibrin, cellulose, and rubber; plastics such as polyethylene (including, for example, high-density polyethylene (HDPE)), PEEK (polyetheretherketone), and polytetrafluoroethylene; metals such as titanium, titanium alloy, stainless steel, and cobalt chromium alloy; metal oxides; non-metal oxides; silicone; bioactive glass; ceramic material such as, for example, aluminum oxide, zirconium oxide, and calcium phosphate; other suitable materials such as demineralized bone matrix; and combinations thereof. The term "polymer" as used herein refers to any of numerous natural and synthetic compounds of usually high molecular weight consisting of up to millions of repeated linked units, each a relatively simple molecule. The term "implant" as used herein includes implant-related materials that are associated with the implant and are also introduced into a human or animal body in conjunction with the implant.

[0030] In one embodiment of the invention, an IFBM creates a binding interface that mediates the attachment of growth factors to the surface of an implant. In some embodiments, implants prepared according to the methods of the invention will have growth factors specifically attached to the surface of the implant; the rate of diffusion of the growth factor away from the site of the implant can vary depending on the affinity of the analyte module for the growth factor in question and thus implants can be prepared with varying rates of diffusion of growth factors. In embodiments involving the attachment of growth factors to the surface of an implant, the growth factor will have a positive effect such as, for example, accelerating the healing process, reducing the amount of growth factor required for healing, and minimizing the side effects caused by using supraphysiological doses of the growth factor. Growth factors of particular interest either as analyte modules or as factors that bind to analyte modules include, for example, BMP-2, BMP-7, PDGF, FGF, and TGF.beta..

[0031] Thus, the present invention provides methods for preparing an implant to be surgically placed into a patient wherein the device is coated with a layer comprising at least one IFBM. In some embodiments, the method comprises the steps of: (a) applying an IFBM coating to the implant, wherein the IFBM comprises an implant module that specifically binds to the implant and an analyte module that specifically binds a growth factor; (b) applying the growth factor to the surface of the implant by dipping, spraying, or brushing a solution containing the growth factor onto the implant; (c) placing the implant into a subject using appropriate surgical techniques which will be known to those of skill in the art.

[0032] Alternatively, a method for coating an implant so that the implanted device promotes growth factor attachment comprises the steps of: (a) applying an IFBM coating to the implant, wherein the IFBM comprises an implant module that specifically binds the implant and an analyte module that specifically binds growth factor at an implant site; and (b) placing the implant in a subject at the implant site; whereby growth factor produced in the host binds to the implant via the IFBM. The enhanced presence of growth factor at the implant site enhances healing of adjacent tissue and integration of the implant into the adjacent tissue.

[0033] In one embodiment of the invention, an IFBM mediates cell attachment to the surface of an implant. By enhancing cell adhesion and tissue integration, the IFBMs of the invention can accelerate healing and improve the function of the implanted device. Thus, in accordance with the present invention, a method for preparing an implant to be surgically placed into a patient can comprise: (a) applying an IFBM coating to the implant, wherein the IFBM comprises at least one implant module that specifically binds the implant and at least one analyte module that specifically binds to at least one type of cell; and (b) placing the implant in a subject at the implant site, whereby cells bind to the IFBM coating on the implant.

[0034] In some embodiments, a method for preparing an implant comprises: (a) applying an IFBM coating to the implant, wherein the IFBM comprises at least one implant module that specifically binds the implant and at least one analyte module that specifically binds at least one type of cell; and (b) applying cells to the surface of the implant, for example, by dipping the implant into a solution containing the cells or brushing a solution containing the cells onto the implant. The implant may then be placed into a subject (i.e., a human patient or an animal patient). By "patient" as used herein is intended either a human or an animal patient.

[0035] In another embodiment of the invention, an implant is coated with more than one type of IFBM in order to provide a coating with multiple functionalities. For example, an implant coating can comprise a first IFBM having an analyte module that binds a cell and a second IFBM having an analyte module that binds a growth factor. A coating comprising these IFBMs would bind both cells and growth factor to the surface of the implant. In some embodiments, these IFBMs would be intermingled in the coating so that the bound growth factor is in close proximity to the bound cells. In one embodiment, a coating comprises an IFBM that binds to mesenchymal stem cells and an IFBM that binds to the growth factor BMP-2; the BMP-2 would trigger the differentiation of the stem cells into osteoblasts. In other embodiments, an implant coating can comprise a mixture of at least two different IFBMs which differ in either or both their implant module and their analyte module. In another embodiment, a coating comprises a multi-functional IFBM which has two analyte modules, one of which binds to a cell and one of which binds to a growth factor.

[0036] Binding modules (i.e., implant modules and/or analyte modules) may be peptides, antibodies or antibody fragments, polynucleotides, oligonucleotides, complexes comprising any of these, or various molecules and/or compounds. Binding modules which are peptides may be identified as described in pending U.S. patent application Ser. No. 10/300,694, filed Nov. 20, 2002 and published on Oct. 2, 2003 as publication number 20030185870. In some embodiments, binding modules may be identified by screening phage display libraries for binding to materials including biocompatible materials (i.e., "biomaterials") such as titanium, stainless steel, cobalt-chrome alloy, polyurethane, polyethylene or silicone.

[0037] In some embodiments of the invention, the analyte module is a bioactive peptide or binds to a bioactive peptide. These bioactive peptides may be fragments of native proteins that retain the biological effect of the native protein, as is well-known in the art. For example, TP508 is a synthetic peptide derived from thrombin which represents amino acids 183-200 of human thrombin and has been shown to accelerate fracture healing (see, e.g., Wang et al. (2002) Trans ORS 27: 234). TP508 function is believed to be mediated by an RGD sequence within the peptide that binds to integrins present on the cell surface (see, e.g., Tsopanoglou et al. (2004) Thromb Haemost. 92(4):846-57.) Similarly, P-15 is a 15 amino acid peptide derived from Type I collagen that represents the cell-binding domain of collagen (see, e.g., Yang et al. (2004) Tissue Eng. 10(7-8): 1148-59). P-15 has been shown to enhance new bone formation (see, e.g., Scarano et al. (2003). Implant Dent. 12(4): 318-24.). Bioactive peptides can also be fragments of growth factors. For example, Saito et al. (J Biomed Mater Res A. 2005 72A(1): 77-82) have shown that a synthetic peptide representing amino acids 73-92 of BMP-2 retains BMP-2 biological activities including binding to a BMP-2 receptor, activating gene expression and inducing ectopic bone formation.

[0038] Any implant module may be combined with any analyte module to create an IFBM of the invention so long as the desired activity is provided; that is, so long as the IFBM specifically binds to a suitable implant and has a suitable effect conferred by the analyte module, i.e., the ability to bind to BMP-2. One of skill in the art will appreciate that a variety of types and numbers of implant modules may be combined with a variety of types and numbers of analyte modules to create an IFBM of the invention. Thus, for example, one or more implant modules may be linked with one or more analyte modules to create an IFBM. One of skill will be able to select suitable implant module(s) and analyte module(s) depending on the material of which an implant is made and the desired activity to be conferred by the analyte module(s).

[0039] The term "antibody" as used herein includes single chain antibodies. Thus, an antibody useful as a binding module may be a single chain variable fragment antibody (scFv). A single chain antibody is an antibody comprising a variable heavy and a variable light chain that are joined together, either directly or via a peptide linker, to form a continuous polypeptide. The term "single chain antibody" as used herein encompasses an immunoglobulin protein or a functional portion thereof, including but not limited to a monoclonal antibody, a chimeric antibody, a hybrid antibody, a mutagenized antibody, a humanized antibody, and antibody fragments that comprise an antigen binding site (e.g., F.sub.ab and F.sub.v antibody fragments).

[0040] Phage display technology is well-known in the art. Using phage display, a library of diverse peptides can be presented to a target substrate, and peptides that specifically bind to the substrate can be selected for use as binding modules. Multiple serial rounds of selection, called "panning," may be used. As is known in the art, any one of a variety of libraries and panning methods can be employed to identify a binding module that is useful in the methods of the invention. For example, libraries of antibodies or antibody fragments may be used to identify antibodies or fragments that bind to particular cell populations or to viruses (see, e.g., U.S. Pat. Nos. 6,174,708; 6,057,098; 5,922,254; 5,840,479; 5,780,225; 5,702,892; and 5,667,988). Panning methods can include, for example, solution phase screening, solid phase screening, or cell-based screening. Once a candidate binding module is identified, directed or random mutagenesis of the sequence may be used to optimize the binding properties of the binding module. The terms "bacteriophage" and "phage" are synonymous and are used herein interchangeably.

[0041] A library can comprise a random collection of molecules. Alternatively, a library can comprise a collection of molecules having a bias for a particular sequence, structure, or conformation. See, e.g., U.S. Pat. Nos. 5,264,563 and 5,824,483. Methods for preparing libraries containing diverse populations of various types of molecules are known in the art, and numerous libraries are also commercially available. Methods for preparing phage libraries can be found, for example, in Kay et al. (1996) Phage Display of Peptides and Proteins (San Diego, Academic Press); Barbas (2001) Phage Display: A Laboratory Manual (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.)

[0042] A binding module (i.e., implant module or analyte module) that is a peptide comprises about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 50, 60, 70, 80, 90, 100, 200, or up to 300 amino acids. Peptides useful as a binding module can be linear, branched, or cyclic, and can include non-peptidyl moieties. The term "peptide" broadly refers to an amino acid chain that includes naturally occurring amino acids, synthetic amino acids, genetically encoded amino acids, non-genetically encoded amino acids, and combinations thereof. Peptides can include both L-form and D-form amino acids.

[0043] A peptide useful as a binding module can be subject to various changes, substitutions, insertions, and deletions where such changes provide for certain advantages in its use. Thus, the term "peptide" encompasses any of a variety of forms of peptide derivatives including, for example, amides, conjugates with proteins, cyclone peptides, polymerized peptides, conservatively substituted variants, analogs, fragments, chemically modified peptides, and peptide mimetics. Any peptide that has desired binding characteristics can be used in the practice of the present invention.

[0044] Representative non-genetically encoded amino acids include but are not limited to 2-aminoadipic acid; 3-aminoadipic acid; .beta.-aminopropionic acid; 2-aminobutyric acid; 4-aminobutyric acid (piperidinic acid); 6-aminocaproic acid; 2-aminoheptanoic acid; 2-aminoisobutyric acid; 3-aminoisobutyric acid; 2-aminopimelic acid; 2,4-diaminobutyric acid; desmosine; 2,2'-diaminopimelic acid; 2,3-diaminopropionic acid; N-ethylglycine; N-ethylasparagine; hydroxylysine; allo-hydroxylysine; 3-hydroxyproline; 4-hydroxyproline; isodesmosine; allo-isoleucine; N-methylglycine (sarcosine); N-methylisoleucine; N-methylvaline; norvaline; norleucine; and ornithine.

[0045] Representative derivatized amino acids include, for example, those molecules in which free amino groups have been derivatized to form amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl groups or formyl groups. Free carboxyl groups can be derivatized to form salts, methyl and ethyl esters or other types of esters or hydrazides. Free hydroxyl groups can be derivatized to form O-acyl or O-alkyl derivatives. The imidazole nitrogen of histidine can be derivatized to form N-im-benzylhistidine.

[0046] The term "conservatively substituted variant" refers to a peptide having an amino acid residue sequence substantially identical to a sequence of a reference peptide in which one or more residues have been conservatively substituted with a functionally similar residue such that the "conservatively substituted variant" will bind to the same binding partner with substantially the same affinity as the parental variant and will prevent binding of the parental variant. In one embodiment, a conservatively substituted variant displays a similar binding specificity when compared to the reference peptide. The phrase "conservatively substituted variant" also includes peptides wherein a residue is replaced with a chemically derivatized residue.

[0047] Examples of conservative substitutions include the substitution of one non-polar (hydrophobic) residue such as isoleucine, valine, leucine or methionine for another; the substitution of one aromatic residue such as tryptophan, tyrosine, or phenylalanine for another; the substitution of one polar (hydrophilic) residue for another such as between arginine and lysine, between glutamine and asparagine, between glycine, alanine, threonine and serine; the substitution of one basic residue such as lysine, arginine or histidine for another; or the substitution of one acidic residue such as aspartic acid or glutamic acid for another.

[0048] While exemplary peptide sequences for use as binding modules in IFBMs of the invention are disclosed herein (e.g., in the sequence listing in SEQ ID NOs: 1-74 and 77-558), one of skill will appreciate that the binding or other properties conferred by those sequences may be attributable to only some of the amino acids comprised by the sequences. Peptides which are binding modules of the present invention also include peptides having one or more substitutions, additions and/or deletions of residues relative to the sequence of an exemplary peptide sequence as disclosed herein, so long as the desired binding properties of the binding module are retained. Thus, binding modules of the invention include peptides that differ from the exemplary sequences disclosed herein by about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids, but that retain the ability of the corresponding exemplary sequence to bind to a particular material or to act as an analyte module. A binding module of the invention that differs from an exemplary sequence disclosed herein will retain at least 25%, 50%, 75%, or 100% of the activity of a binding module comprising an entire exemplary sequence disclosed herein as measured using an appropriate assay.

[0049] That is, binding modules of the invention include peptides that share sequence identity with the exemplary sequences disclosed herein of at least 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater sequence identity. Sequence identity may be calculated manually or it may be calculated using a computer implementation of a mathematical algorithm, for example, GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package of Genetics Computer Group, Version 10 (available from Accelrys, 9685 Scranton Road, San Diego, Calif., 92121, USA). The scoring matrix used in Version 10 of the Wisconsin Genetics Software Package is BLOSUM62 (see Henikoff and Henikoff (1989) Proc. Nat'l. Acad. Sci. USA 89: 10915). Alignments using these programs can be performed using the default parameters.

[0050] A peptide can be modified, for example, by terminal-NH.sub.2 acylation (e.g., acetylation, or thioglycolic acid amidation) or by terminal-carboxylamidation (e.g., with ammonia or methylamine). Terminal modifications are useful to reduce susceptibility by proteinase digestion, and to therefore prolong a half-life of peptides in solutions, particularly in biological fluids where proteases can be present.

[0051] Peptide cyclization is also a useful modification because of the stable structures formed by cyclization and in view of the biological activities observed for such cyclic peptides. Methods for cyclizing peptides are described, for example, by Schneider & Eberle (1993) Peptides. 1992: Proceedings of the Twenty-Second European Peptide Symposium, Sep. 13-19, 1992, Interlaken, Switzerland, Escom, Leiden, The Netherlands.

[0052] Optionally, a binding module peptide can comprise one or more amino acids that have been modified to contain one or more halogens, such as fluorine, bromine, or iodine, to facilitate linking to a linker molecule. As used herein, the term "peptide" also encompasses a peptide wherein one or more of the peptide bonds are replaced by pseudopeptide bonds including but not limited to a carba bond (CH.sub.2--CH.sub.2), a depsi bond (CO--O), a hydroxyethylene bond (CHOH--CH.sub.2), a ketomethylene bond (CO--CH.sub.2), a methylene-oxy bond (CH.sub.2--O), a reduced bond (CH.sub.2--NH), a thiomethylene bond (CH.sub.2--S), an N-modified bond (--NRCO--), and a thiopeptide bond (CS--NH). See e.g., Garbay-Jaureguiberry et al. (1992) Int. J. Pept. Protein Res. 39: 523-527; Tung et al. (1992) Pept. Res. 5: 115-118; Urge et al. (1992) Carbohydr. Res. 235: 83-93; Corringer et al. (1993) J. Med. Chem. 36: 166-172; Pavone et al. (1993) Int. J. Pept. Protein Res. 41: 15-20.

[0053] Representative peptides that specifically bind to surfaces of interest (including titanium, stainless steel, collagen, and poly glycolic acid (PGA)) and therefore are suitable for use as binding modules in IFBMs of the invention are set forth in the sequence listing and are further described herein below. While exemplary peptide sequences are disclosed herein, one of skill will appreciate that the binding properties conferred by those sequences may be attributable to only some of the amino acids comprised by the sequences. Thus, a sequence which comprises only a portion of an exemplary sequence disclosed herein may have substantially the same binding properties as the full-length exemplary sequence. Thus, also useful as binding modules are sequences that comprise only 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 of the amino acids in a particular exemplary sequence, and such amino acids may be contiguous or non-contiguous in the exemplary sequence. Such amino acids may be concentrated at the amino-terminal end of the exemplary peptide (for example, 4 amino acids may be concentrated in the first 5, 6, 7, 8, 9, 10, 11, or 12 amino acids of the peptide) or they may be dispersed throughout the exemplary peptide but nevertheless be responsible for the binding properties of the peptide. For example, a peptide that specifically binds to BMP-2 may comprise all or part of a sequence motif such as that described in Example 3 and set forth in SEQ ID NO:27 or 28. Thus, a peptide that specifically binds to BMP-2 may have a sequence that conforms to each requirement of the sequence motif as set forth in SEQ ID NO:27 or 28, or it may have a sequence that conforms to 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the requirements of the sequence motif. The sequence motif set forth in SEQ ID NO:27 can be described as having four "requirements" which limit the amino acids that are present at positions 1, 4, 6, and 7. A peptide that specifically binds to BMP-2 may have a sequence as set forth in SEQ ID NO:11 which conforms to all four of those requirements, or it may have a sequence as set forth in SEQ ID NO:21 which conforms to three of those four requirements. Both of these types of sequences are provided by the present invention.

[0054] In some embodiments, the IFBM has been constructed so as to mimic the biological effects of protein growth factors. In these embodiments, the analyte module comprises a peptide which comprises an amino acid sequence which binds to the BMP receptor BMPRI and also comprises an amino acid sequence which binds to the BMP receptor BMPRII (see, for example, Example 6). These receptors are well-known in the art and are also commercially available (for example, from R&D Systems, Minneapolis, Minn., Cat. Nos. 315-BR and 811-BR). In these embodiments, the analyte module has BMP activity as measured, for example, by techniques known in the art and described in Example 6. While the invention is not bound by any particular mechanism of operation, it is believed that by binding to each of BMPRI and BMPRII, the analyte module will encourage the heterodimerization of these receptors, thereby triggering signaling via the BMP-SMAD pathway. In this manner, an IFBM could be constructed and used to coat the surface of an implant so as to trigger signaling via the BMP-SMAD pathway without the addition of BMP itself. Generally, in the native BMP-SMAD pathway, heterodimerization of the BMP type I and type II receptors is required for signaling (see, e.g., Chen et al. (2004) Growth Factors 22: 233-241). Dimerization brings the cytoplasmic domains of the type I and type II receptors into proximity, allowing the constitutively active type II receptor kinase to phosphorylate the type I receptor. The phosphorylation of the cytoplasmic domain of the type I receptor activates its latent kinase activity which in turn activates Smad proteins. After release from the receptor, the phosphorylated Smad proteins associate with Smad4 and this complex is translocated into the nucleus to function with other proteins as transcription factors and regulate responsive genes (Chen et al. (2004) Growth Factors 22: 233-241). Collectively, this can be referred to as the downstream Smad or BMP-SMAD signal transduction pathway and genes activated thereby. Proteins produced as a result of activation of the Smad or BMP-SMAD pathway can be referred to as Smad-activated downstream protein products.

[0055] Binding modules of the present invention that are peptides can be synthesized by any of the techniques that are known to those skilled in the art of peptide synthesis. Representative techniques can be found, for example, in Stewart & Young (1969) Solid Phase Peptide Synthesis, (Freeman, San Francisco, Calif.); Merrifield (1969) Adv. Enzymol. Relat. Areas Mol. Biol. 32: 221-296; Fields & Noble (1990) Int. J. Pept. Protein Res. 35: 161-214; and Bodanszky (1993) Principles of Peptide Synthesis, 2nd Rev. Ed. (Springer-Verlag, Berlin). Representative solid phase synthesis techniques can be found in Andersson et al. (2000) Biopolymers 55: 227-250, references cited therein, and in U.S. Pat. Nos. 6,015,561; 6,015,881; 6,031,071; and 4,244,946. Peptide synthesis in solution is described in Schroder & Lake (1965) The Peptides (Academic Press, New York, N.Y.). Appropriate protective groups useful for peptide synthesis are described in the above texts and in McOmie (1973) Protective Groups in Organic Chemistry (Plenum Press, London). Peptides, including peptides comprising non-genetically encoded amino acids, can also be produced in a cell-free translation system, such as the system described by Shimizu et al. (2001) Nat Biotechnol 19: 751-755. In addition, peptides having a specified amino acid sequence can be purchased from commercial sources (e.g., Biopeptide Co., LLC of San Diego, Calif.), and PeptidoGenics of Livermore, Calif.).

[0056] The binding modules are connected by at least one linker to form an IFBM of the invention. In some embodiments, IFBMs consisting of binding modules which are peptides are synthesized as a single continuous peptide; in these embodiments, the linker is simply one of the bonds in the peptide. In other embodiments of the invention, a linker can comprise a polymer, including a synthetic polymer or a natural polymer. Representative synthetic polymers which are useful as linkers include but are not limited to: polyethers (e.g., polyethylene glycol; PEG), polyesters (e.g., polylactic acid (PLA) and polyglycolic acid (PGA), polyamides (e.g., nylon), polyamines, polyacrylic acids, polyurethanes, polystyrenes, and other synthetic polymers having a molecular weight of about 200 daltons to about 1000 kilodaltons. Representative natural polymers which are useful as linkers include but are not limited to: hyaluronic acid, alginate, chondroitin sulfate, fibrinogen, fibronectin, albumin, collagen, and other natural polymers having a molecular weight of about 200 daltons to about 20,000 kilodaltons. Polymeric linkers can comprise a diblock polymer, a multi-block copolymer, a comb polymer, a star polymer, a dendritic polymer, a hybrid linear-dendritic polymer, or a random copolymer.

[0057] A linker can also comprise a mercapto(amido)carboxylic acid, an acrylamidocarboxylic acid, an acrlyamido-amidotriethylene glycolic acid, and derivatives thereof. See, for example, U.S. Pat. No. 6,280,760. Where a linker comprises a peptide, the peptide can include sequences known to have particular biological functions, such as YGD and GSR.

[0058] Methods for linking a linker molecule to a binding domain will vary according to the reactive groups present on each molecule. Protocols for linking using reactive groups and molecules are known to one of skill in the art. See, e.g., Goldman et al. (1997) Cancer Res. 57: 1447-1451; Cheng (1996) Hum. Gene Therapy 7: 275-282; Neri et al. (1997) Nat. Biotechnol. 19: 958-961; Nabel (1997) Current Protocols in Human Genetics, vol. on CD-ROM (John Wiley & Sons, New York); Park et al. (1997) Adv. Pharmacol. 40: 399-435; Pasqualini et al. (1997) Nat. Biotechnol. 15: 542-546; Bauminger & Wilchek (1980) Meth. Enzymol. 70: 151-159; U.S. Pat. Nos. 6,280,760 and 6,071,890; and European Patent Nos. 0 439 095 and 0 712 621.

[0059] The surfaces of medical devices are coated by any suitable method, for example, by dipping, spraying, or brushing the IFBM onto the device. The coating may be stabilized, for example, by air drying or by lyophilization. However, these treatments are not exclusive, and other coating and stabilization methods may be employed. Suitable methods are known in the art. See, e.g., Harris et al. (2004) Biomaterials 25: 4135-4148 and U.S. patent application Ser. No. 10/644,703, filed Aug. 19, 2003 and published on May 6, 2004 with Publication No. 20040087505.

[0060] All publications and patent applications mentioned in the specification are indicative of the level of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

[0061] Many modifications and other embodiments of the inventions set forth herein will come to mind to one skilled in the art to which these inventions pertain having the benefit of the teachings presented in the foregoing descriptions and the associated drawings. Therefore, it is to be understood that the inventions are not to be limited to the specific embodiments disclosed and that modifications and other embodiments are intended to be included within the scope of the appended claims. Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation.

EXPERIMENTAL

Example 1

Isolation of Peptides that Bind Titanium

[0062] Ten different phage display libraries were screened for binding to titanium beads. Titanium (Ti.sub.6Al.sub.4V) beads of approximately 5/32 of an inch diameter were washed with 70% ethanol, 40% nitric acid, distilled water, 70% ethanol, and acetone to remove any surface contaminants. One titanium bead was placed per well of 96-well polypropylene plate (Nunc).

[0063] Nonspecific binding sites on the titanium and the surface of the polypropylene were blocked with 1% bovine serum albumin (BSA) in phosphate-buffered saline (PBS; Sigma Chemical Co., St. Louis, Mo., Cat. #P-3813). The plate was incubated for 1 hour at room temperature with shaking at 50 rpm. The wells were then washed 5 times with 300 .mu.l of PBS. Each library was diluted in PBS+1% BSA and was added at a concentration of 10.sup.10 pfu/ml in a total volume of 250 .mu.l. After a 3-hour incubation at room temperature and shaking at 50 rpm, unbound phage were removed by washing 3 time with 300 .mu.l of Phosphate Buffered Saline-Tween.TM. 20 (PBS-T; Sigma Chemical Co., St. Louis, Mo., Cat. #P-3563). To recover the phage bound to the titanium beads, bound phage were released by treating with 50 mM glycine, pH 2 for 10 minutes followed by a 10 minute treatment with 100 mM ethanolamine, pH 12. The eluted phage were pooled, neutralized with 200 .mu.l of 200 mM NaPO.sub.4 pH 7. The eluted phage and the beads were added directly to E. coli DH5.alpha.F' cells in 2.times.YT media. The mixture was incubated overnight in a 37'C shaker at 210 rpm. Phage supernatant was then harvested after spinning at 8500.times.g for 10 minutes. Second and third rounds of selection were performed in a similar manner to that of the first round, using the 50 .mu.l of amplified phage from the previous round as input diluted with 200 .mu.l of PBS+1% BSA. The fourth round of selection was carried out in a similar fashion; however, the washes were modified. After a 4 hour binding reaction, the beads were washed five times with PBS-T (Sigma Chemical Co., St. Louis, Mo., Cat. #P-3563), the beads were moved to a clean polypropylene plate with 2 ml wells, 1 ml of PBS+1% BSA was added to each well and the washing was incubated overnight at room temperature with shaking at 50 rpm. The next morning the phage were eluted and amplified in the same manner described for rounds 1-3. Individual clonal phage were then isolated and tested by plating out dilutions of phage pools to obtain single plaques.

[0064] To detect phage that specifically bound to titanium, conventional ELISAs were performed using an anti-M13 phage antibody conjugated to HRP, followed by the addition of chromogenic agent ABTS. Relative binding strengths of the phage were determined by testing serial dilutions of the phage for binding to titanium in an ELISA.

[0065] The DNA sequence encoding peptides that specifically bound titanium was determined. The sequence encoding the peptide insert was located in the phage genome and translated to yield the corresponding amino acid sequence displayed on the phage surface.

[0066] Representative peptides that specifically bind titanium are listed in Table 1 and are set forth as SEQ ID NOs:1-8. The binding of phage displaying these peptides to titanium beads is shown in FIG. 1.

TABLE-US-00001 TABLE 1 Titanium Binding Peptides Synthetic SEQ. Clone Peptide ID. Number Number Displayed Peptide NO. AP06-22 AFF-6002 SSHKHPVTPRFFVVESR 1 AP06-23 AFF-6003 SSCNCYVTPNLLKHKCYKICSR 2 AP06-24 AFF-6004 SSCSHNHHKLTAKHQVAHKCSR 3 AP06-25 AFF-6005 SSCDQNDIFYTSKKSHKSHCSR 4 AP06-26 AFF-6006 SSSSDVYLVSHKHHLTRHNSSR 5 AP06-27 AFF-6007 SSSDKCHKHWYCYESKYGGSSR 6 AP06-28 HHKLKHQMLHLNGG 7 AP06-29 GHHHKKDQLPQLGG 8

[0067] The displayed peptides were then synthesized with a C-terminal biotin residue and tested for binding to titanium. Results are shown in FIG. 2. Briefly, peptide stock solutions were made by dissolving the powder in 100% DMSO to make a 1 mM solution of peptide. Serial dilutions of the peptide were made in PBS-T. Titanium beads blocked with 1% non-fat dry milk in PBS were incubated with various concentrations of peptide for 1 hour at room temperature with shaking. The beads were washed 3 times with PBS-T. Streptavidin-alkaline phosphatase (SA-AP) from USB (United States Biochemical, catalog #11687) was added (1:1000 in PBS-T) and incubated 1 hour at room temperature with shaking. The beads were washed 3 times with PBS-T and the amount of peptide:SA-AP was determined by adding PNPP (Sigma-Aldrich, Inc., SigmaFast tablets, catalog #N1891) and allowing the color to develop for about 10 minutes. Quantitation was carried out by transferring the solution to a clear microtiter plate and reading the absorbance at 405 nm on a Molecular Dynamics Plate Reader. The peptide "9003" is known in the art. This peptide was identified by phage display as binding to the enzyme hexokinase; it serves as a negative control for this experiment (see, e.g., Hyde-DeRuyscher et al. (2000) Chem. Biol. 7: 17-25).

Example 2

Role of Cysteine Residues in Titanium-binding Peptide 6007

[0068] To explore the role of the cysteine residues and disulfide formation in the binding of peptide 6007 to titanium, a peptide was synthesized AFF6010 (Table 2) in which the cysteine residues present in the titanium-binding peptide AFF6007 were changed to serine residues. The sequence of peptide AFF6010 (SSSDKSHKHWYSYESKYGGSGSSGK) is set forth in SEQ ID NO:9, while the sequence of peptide AFF6007 (SSSDKCHKHWYCYESKYGGSGSSGK) is set forth in SEQ ID NO:10. The peptides AFF6007 and AFF6010 were then conjugated to biotin and compared for binding to titanium beads as follows.

[0069] Titanium beads were blocked with 1% BSA in PBS for 30 minutes at room temperature. Stock solutions of peptide AFF6007 and AFF6010 were prepared by dissolving 1-2 mg peptide in water. The final concentration of each peptide was determined using the optical density at 280 nm and the extinction coefficient of each peptide. AFF6007 and AFF6010 were prepared at 200 .mu.M. A dilution series was then prepared for each peptide sample. Each peptide underwent a threefold dilution in 1% BSA in PBS.

[0070] The peptides were incubated with the titanium beads for 1 hour at room temperature. Beads were then washed two times with PBS/Tween.TM. 20. Streptavidin-alkaline phosphatase was then added to the beads at 1:500 for 30 minutes at room temperature. Beads were washed two times with PBS/Tween.TM. 20. PNPP was used to develop the assay and the absorbance was recorded at 405 nm.

[0071] The results, which are shown in FIG. 3, demonstrate that peptides AFF6007 and AFF6010 both bind to titanium. An estimate of the relative affinity of a peptide for titanium can be made by determining the concentration of peptide that gives one-half the maximal signal (Table 2). The complete elimination of the cysteine residues in AFF6007 decreases the affinity of the peptide for titanium by about 10-fold but does not eliminate it (Table 2). Therefore, the cysteine residues are not required for binding to titanium but do increase the affinity of the peptide for titanium.

TABLE-US-00002 TABLE 2 Relative Affinity of Titanium-binding Peptides [peptide] Sample 1/2 maximal signal AFF6007 0.35 .mu.M AFF6010 3 .mu.M

Example 3

Peptides that Specifically Bind to Bone Morphogenic Protein 2 ("BMP-2")

Isolation and Analysis of Peptides

[0072] Ten different phage display libraries were screened for binding to BMP-2. BMP-2 (Medtronic) was biotinylated with NHS-biotin (Pierce) to produce a labeled protein with an average of one biotin per protein molecule. This protein was immobilized on streptavidin (SA) coated plates and used as target for phage display. As an alternative method to display the protein, BMP-2 was also linked to sepharose beads using NHS-succinimide chemistry according to the instructions of the manufacturer (Amersham-Pharmacia, Ref. No. 18-1022-29, entitled "Coupling through the Primary Amine of a Ligand to NHS-activated Sepharose 4 Fast Flow," pp. 105-108) and the beads were used as a solid phase to separate free from unbound phage. After 3 rounds of selection, individual clones from each format were tested for binding to BMP-2 on SA coated plates utilizing a conventional ELISA using an anti-M13 phage antibody conjugated to HRP, followed by the addition of chromogenic agent ABTS.

[0073] The DNA sequence encoding peptides that specifically bound to BMP-2 was determined. The sequence encoding the peptide insert was located in the phage genome and translated to yield the corresponding amino acid sequence displayed on the phage surface. Representative peptides that specifically bind BMP-2 are listed in Table 3 and are set forth as SEQ ID NOs:11-26. In some embodiments, an exemplary binding module of the invention comprises only that portion of the sequence shown in uppercase letters.

TABLE-US-00003 TABLE 3 Peptides that Specifically Bind to BMP-2 Synthetic SEQ. Clone Peptide ID. Number Number Sequence NO. AP02-45 AFF-2011 ##STR00001## 11 AP02-46 ##STR00002## 12 AP02-47 ##STR00003## 13 AP02-48 AFF-2006 ##STR00004## 14 AP02-49 ##STR00005## 15 AP02-50 AFF-2007 ##STR00006## 16 AP02-51 ##STR00007## 17 AP02-52 AFF-2010 ##STR00008## 18 AP02-53 ##STR00009## 19 AP02-54 AFF-2008 ##STR00010## 20 AP02-55 ##STR00011## 21 AP02-56 ##STR00012## 22 AP02-57 ##STR00013## 23 AP02-58 ##STR00014## 24 AP02-59 AFF-2012 ##STR00015## 25 AP02-60 AFF-2009 ##STR00016## 26

[0074] The peptides that were identified fall into 2 different "sequence clusters". Each sequence cluster contains a common sequence motif. For the first sequence cluster of BMP-binding peptides, the common motif (designated "Motif 1" and set forth in SEQ ID NO:27) is Aromatic-X-X-Phe-X-"Small"-Leu (Aromatic=Trp, Phe, or Tyr; X=any amino acid; "Small"=Ser, Thr, Ala, or Gly). Motif 1 is at least partially found in SEQ ID NOs:11-24 as shown in Table 3 above. The second sequence cluster motif (also set forth in SEQ ID NO:28) comprises the sequence (Leu or Val)-X-Phe-Pro-Leu-(Lys or Arg)-Gly. This motif, designated Motif 2, is found in SEQ ID NOs:25 and 26 as shown in Table 3 above. Exemplary binding modules also comprise sequences which meet the requirements of this or other sequence motifs identified herein (i.e., which contain a sequence which falls within these motifs).

[0075] Additional experiments were conducted to determine additional characteristics of sequences that bind to BMP-2. Specifically, in order to determine whether there were additional preferred amino acids surrounding these motifs, further screening was conducted. Focused libraries were designed and cloned into the mAEK phage display vector and the resultant phage were screened for binding to BMP-2, as further discussed below. The focused library for Motif 1 was designed to express peptides containing the following sequence: X-X-X-X-X-(W/L/C/Y/F/S)-X-X-(W/L/C/Y/F/S)--X-(A/G/N/S/T)-(L/F/I/M/V)-X-X-- X-X-X, where X represents any of the 20 naturally occurring amino acids and positions in parentheses are restricted to the amino acids listed within the parentheses. These peptides were encoded by oligonucleotides comprising the sequence 5'-GATCCTCGAGNNNKNNKNNKNNKNNKTNBNNKNNKTNBNNKRSYNTKNNKN NKNNKNNKNNKTCTAGAGCGCTACG 3' (where "N" is any of the 4 nucleotides A, G, C, or T; "K" is G or T; "R" is A or G; "S" is C or G; "B" is C, G, or T; and "Y" is C or T). The focused library for Motif 2 was designed to express peptides containing the following sequence: X-X-X-(L/F/I/M/V)-X-(W/L/C/Y/F/S)-(P/S/T/A)-(L/F/I/M/V)-(I/M/T/N/K/S/R)-X- -X-X-X-X-X-X-X. These peptides were encoded by oligonucleotides comprising the sequence 5'-GATCCTCGANNNKNNKNNKNTKNNKTNBNCKNTKANKNNKNNKNNKNNKNN KNNKNNKNNKTCTAGAGCGCTACG 3'.

[0076] The following is provided as an exemplary library construction scheme for the Motif 1 focused library. As will be appreciated by one of skill in the art, a similar strategy can be used for other libraries. To produce the focused library for Motif 1, an oligonucleotide comprising the sequence above flanked by appropriate restriction enzyme sites was synthesized. This oligonucleotide contained the sequence 5'-GATCCTCGAGNNNKNNKNNKNNKNNKTNBNNKNNKTNBNNKRSYNTKNNKNNKN NKNNKNNKTCTAGAGCGCTACG-3'. In this sequence, the underlined sequences CTCGAG and TCTAGA represent the XhoI and XbaI restriction enzyme sites used to clone the library into the phage vector. A short primer is annealed to the oligonucleotide and the complementary strand synthesized using a DNA polymerase. The resulting double-stranded DNA molecule is digested with XhoI and XbaI and cloned into the phage display vector. The ligated DNA is transformed into an appropriate bacterial host and amplified to generate the phage library.

[0077] The focused libraries for Motif 1 and Motif 2 were screened for binding to BMP-2 using biotinylated BMP-2 immobilized on streptavidin-coated plates as described above. After two rounds of selection on BMP-2, the libraries had been enriched for phage displaying peptides that bind to BMP-2. The pools of enriched phage were plated onto a lawn of bacterial cells to isolate individual phage. Individual phage clones were tested for binding to BMP-2 using an ELISA-type assay and an anti-M13 phage antibody conjugated to HRP (Amersham Biosciences #27-9421-01), followed by addition of the chromogenic reagent ABTS (Sigma Chemical Co., St. Louis, Mo., Cat. #A3219).

[0078] The DNA sequence encoding peptides that specifically bound to BMP-2 was determined. The sequence encoding the peptide insert was located in the phage genome and translated to yield the corresponding amino acid sequence displayed on the phage surface.

[0079] Representative peptides from the motif-based focused libraries that specifically bind BMP-2 are listed in Tables 4 and 5 and are set forth as SEQ ID NOs:44-71 and 77-92. In some embodiments, an exemplary binding module of the invention comprises only that portion of the sequence shown in uppercase letters, or comprises only a sequence falling within a motif or a consensus sequence identified based on these sequences (i.e., comprises a sequence falling within the scope of Motif 1, Motif 1a, or Motif 2, or comprises the consensus sequence identified in SEQ ID NO:72, 74, or 93).

TABLE-US-00004 TABLE 4 BMP Binding Peptides from Motif 1 Focused Library SEQ. ID Clone ID Sequence NO. AP02-01 ##STR00017## 44 AP02-02 ##STR00018## 45 AP02-03 ##STR00019## 46 AP02-04 ##STR00020## 47 AP02-05 ##STR00021## 48 AP02-06 ##STR00022## 49 AP02-07 ##STR00023## 50 AP02-08 ##STR00024## 51 AP02-09 ##STR00025## 52 AP02-10 ##STR00026## 53 AP02-11 ##STR00027## 54 AP02-12 ##STR00028## 55 AP02-13 ##STR00029## 56 AP02-14 ##STR00030## 57 AP02-15 ##STR00031## 58 AP02-16 ##STR00032## 59 AP02-17 ##STR00033## 60 AP02-18 ##STR00034## 61 AP02-19 ##STR00035## 62 AP02-20 ##STR00036## 63 AP02-21 ##STR00037## 64 AP02-22 ##STR00038## 65 AP02-23 ##STR00039## 66 AP02-24 ##STR00040## 67 AP02-25 ##STR00041## 68 AP02-26 ##STR00042## 69 AP02-27 ##STR00043## 70 AP02-44 ##STR00044## 71

[0080] The results of an analysis of all the peptide sequences from Tables 3 and 4 that bind BMP-2 and contain Motif 1 was generated and is shown in FIG. 7. From an alignment of the 40 BMP-binding sequences that contain Motif 1, a consensus sequence can be derived (Gly-Gly-Gly-Ala-Trp-Glu-Ala-Phe-Ser-Ser-Leu-Ser-Gly-Ser-Arg-Val; SEQ ID NO: 72) that represents the predominant amino acid found at each position after all the peptides are aligned. Among the 40 sequences, the most conserved amino acids form a core binding motif which represents a subset of all sequences containing Motif 1. This motif, designated "Motif 1a," has the sequence Trp-X-X-Phe-X-X-Leu (SEQ ID NO: 73). While the invention is not bound by any particular mechanism of action, it is believed that in this motif, the Trp, Phe, and Leu residues on the peptide participate in specific interactions with the BMP-2 protein that are responsible for the binding of the peptide to BMP. On this basis, it was hypothesized that other peptides that contain this core binding motif will also bind to BMP.

[0081] To test this idea, an oligonucleotide cassette was designed to express a peptide which contained this core binding Motif 1a in the context of a peptide sequence which also contained consensus residues identified for other positions in the sequence that flanked the core binding motif (see FIG. 8; SEQ ID NO: 74). Incidentally, none of the BMP-binding peptides previously isolated by phage display actually contain this exact sequence (see, e.g., Table 4). This oligonucleotide cassette was cloned into the mAEK phage display vector and the resulting phage, designated AP02-61, was tested for binding to BMP-2 and compared to other phage displaying BMP-binding peptides (results for some phage are shown in FIG. 9). At least one phage tested (designated AP02-37) showed binding at a level equivalent to or below that of the display vector mAEK. In some embodiments, an exemplary binding module of the invention comprises only that portion of the sequence shown in uppercase letters.

TABLE-US-00005 TABLE 5 BMP-Binding Peptides from Motif-2 Focused Library SEQ. ID. Clone ID Sequence NO.: AP02-28 ##STR00045## 77 AP02-29 ##STR00046## 78 AP02-30 ##STR00047## 79 AP02-31 ##STR00048## 80 AP02-32 ##STR00049## 81 AP02-33 ##STR00050## 82 AP02-34 ##STR00051## 83 AP02-35 ##STR00052## 84 AP02-36 ##STR00053## 85 AP02-37 ##STR00054## 86 AP02-38 ##STR00055## 87 AP02-39 ##STR00056## 88 AP02-40 ##STR00057## 89 AP02-41 ##STR00058## 90 AP02-42 ##STR00059## 91 AP02-43 ##STR00060## 92

[0082] From an alignment of the peptides from Tables 3 and 5 that contain Motif 2, a consensus sequence can be derived (Gly-Gly-Ala-Leu-Gly-Phe-Pro-Leu-Lys-Gly-Glu-Val-Val-Glu-Gly-Trp-Ala; SEQ ID NO: 93; see FIG. 10) that represents the predominant amino acid found at each position after all the peptides are aligned. Among the sequences examined, the most conserved amino acids form a core binding motif designated "Motif 2a," which has the sequence Leu-X-Phe-Pro-Leu-Lys-Gly (SEQ ID NO: 94).

[0083] Motif 2 appears to be more restricted in sequence than Motif 1 in that Motif 2 imposes requirements on six positions whereas Motif 1 only imposes requirements on three positions. The Pro and Gly residues in Motif 2 appear to be required for binding since every Motif 2-containing BMP-binding peptide contains the Pro and Gly residues found in the core binding motif. Using the consensus sequence information for Motif 2, BMP-binding peptides can be designed by incorporating the Motif 2 core binding motif into the peptide sequence.

Production of Synthetic Peptides and BMP-2 Binding Assays

[0084] A representative set of the displayed peptides were then synthesized with a C-terminal biotin residue and tested for binding to BMP-2. Results are shown in FIG. 4. Briefly, peptide stock solutions were made by dissolving the powder in 100% DMSO to make a 10 mM solution of peptide, water was then added for a final stock concentration of peptide of 1 mM in 10% DMSO. Serial dilutions of the peptide were made in PBS-T. A dilution series of BMP-2 with concentrations ranging from 100 nM to 0.1 nM was immobilized onto the wells of microtiter plates (Immulon-4.RTM. HBX from Dynex Technologies, Chantilly, Va.) and blocked with 1% BSA. These plates were incubated with various concentrations of peptide for 1 hour at room temperature with shaking. The beads were washed 3 times with PBS-T. Streptavidin-alkaline phosphatase (SA-AP) from USB (United States Biochemical, catalog #11687) was added (1:1000 in PBS-T) and incubated 1 hour at room temperature with shaking. The plates were washed 3 times with PBS-T and the amount of peptide:SA-AP was determined by adding PNPP (Sigma-Aldrich, Inc., SigmaFast tablets, catalog #N1891) and allowing the color to develop for about 10 minutes. Quantitation was carried out by reading the absorbance at 405 nm on a Molecular Dynamics Plate Reader. The results are summarized in FIG. 4.

[0085] To confirm these BMP binding results, the peptides were also tested in an alternate assay format in which the peptide and BMP2 were allowed to bind in solution and then assayed. Briefly, the peptides were synthesized with a biotin group attached to the 8 amino group of a lysine residue at the C-terminus of the peptide. The biotinylated peptides (0-12 pmoles) were mixed with BMP-2 (0-25 pmoles) in solution and allowed to incubate at 37.degree. C. for 30 minutes in a polypropylene plate. The solutions were transferred to a streptavidin-coated plate and incubated for 1 hour at 37.degree. C. to capture the biotinylated peptides. Plates were washed in TBS-Tween.TM. 20 and then incubated with an anti-BMP antibody (1:1000 dilution; R&D systems) for 1 hour at RT. After washing, an alkaline phosphatase-labeled secondary antibody was then added to the plate and incubated at RT for 30 minutes. The plates were washed with TBS-Tween.TM. 20 and the antibody binding was detected using the chromogenic AP substrate pNPP. Representative results are shown in FIG. 11. From this data, the affinity of each BMP-binding peptide for BMP-2 was calculated (Table 6).

TABLE-US-00006 TABLE 6 Estimated Affinity of BMP-binding Peptides for BMP-2 Estimated Peptide Affinity (nM) 2012 9 2009 10 2006 21 2011 55 2007 79 2008 99

BMP-2 Binding Peptides Bind to other BMP proteins

[0086] Bone Morphogenetic Proteins (BMPs) are members of the TGF-beta superfamily which includes BMPs, Transforming Growth Factor-beta (TGF-.beta.) and Growth/Differentiation factors (GDFs). The proteins in the TGF-.beta. superfamily are very similar structurally. The folded structure of the protein backbone is almost identical among all the members of the family. Based on the similarity in structure between the BMPs, we tested the ability of some of the BMP-2-binding peptides to bind BMP-4 and BMP-7. Biotinylated peptides 2007 and 2011 were tested for binding to BMP-2, BMP-4, and BMP-7 as described above. Both 2007 and 2011 bound to all three BMPs while a peptide that binds to an unrelated target (AFF-9001) did not bind to any of the BMPs (FIG. 12).

Example 4

Generation of an IFBM that Immobilizes BMP-2 onto Collagen

[0087] To design a molecule with collagen and BMP-2 binding properties, an IFBM was created that comprised a peptide that binds to collagen and a peptide that binds to BMP-2. Examples of this "hybrid peptide" IFBM are shown in Table 7.

TABLE-US-00007 TABLE 7 IFBMs that bind to Collagen and BMP-2 IFBM SEQ ID # Peptides Peptide Sequence NO: AFF 2009- SSFEPLRFPLKGVPVSRGSSGKDVNSIWMSRVIEWTYDS-NH2 29 7005 0016 AFF 0016- DVNSIWMSRVIEWTYDSGSSGKSSFEPLRFPLKGVPVSR-NH2 30 7006 2009 AFF 2006- SRSSDSAFSSFSALEGSVVSRGSSGKDVNSIWMSRVIEWTYDS-NH2 31 7007 0016 AFF 0016- DVNSIWMSRVIEWTYDSGSSGKSRSSDSAFSSFSALEGSVVSR-NH2 32 7008 2006 AFF 2012- SSSVDLYFPLKGDVVSRGSSGKDVNSIWMSRVIEWTYDS-NH2 33 7009 0016 AFF 0016- DVNSIWMSRVIEWTYDSGSSGKSSSVDLYFPLKGDVVSR-NH2 34 7010 2012 AFF 2007- SRGGEAAAGAWVSFSALESSRGSSGKDVNSIWMSRVIEWTYDS-NH2 35 7014 0016 AFF 0016- DVNSIWMSRVIEWTYDSGSSGKSRGGEAAAGAWVSFSALESSR-NH2 36 7015 2007 AFF 2011- SSDWGVVASAWDAFEALDASRGSSGKDVNSIWMSRVIEWTYDS-NH2 37 7016 0016 AFF 0016- DVNSIWMSRVIEWTYDSGSSGKSSDWGVVASAWDAFEALDASR-NH2 38 7017 2011

[0088] As shown in Table 7, each IFBM contains the collagen binding domain from AFF0016 followed by a short linker sequence which is then linked to a BMP binding sequence from the above example in a "hybrid peptide." These molecules were synthesized in both orientations to assess the effect of N- or C-terminal locations on the ability of the IFBM to bind to collagen or BMP-2.

[0089] To determine if these IFBM's increased the amount of BMP retained by a collagen sponge, we mixed the IFBM with BMP, added the mixture to a sponge, allowed them to bind for 1.5 hours, washed the sponge and detected the bound BMP with anti-BMP antibodies. Briefly, stock IFBM solutions were prepared by weighing 1-2 mg peptide and solubilizing in water. The final peptide concentration was determined by analyzing the peptide absorbance at 280 nm and the extinction coefficient. For each row, 20 .mu.L of peptide were added to each well of a polypropylene microtiter plate. BMP was then added to each of these wells in a threefold dilution series, starting with 32 .mu.M BMP. The IFBM and BMP were allowed to mix at room temperature for 30 minutes.

[0090] To each well, a 2/16'' diameter collagen sponge (Medtronic) was added. The collagen and peptide solutions were allowed to incubate for 1.5 hours at room temperature. Sponges were then rinsed three times with 200 .mu.L Medtronic buffer at 2200 rpm for 1 minute. To each sponge, a primary antibody directed at BMP (diluted 1:1000; R&D Systems #MAB3552) was added for 1 hour at room temperature. A secondary antibody conjugated to alkaline phosphatase (1:5000) was then incubated in the system for 0.5 hour at room temperature. PNPP was used to develop the system and absorbances were read at 405 nm. Results are shown in FIG. 5.

[0091] The results shown in FIG. 5 demonstrate that IFBM AFF7010 retains more BMP on the sponge than the sponges without IFBM. IFBM AFF7008 and AFF7017 increase the amount of BMP on the sponge when compared to no IFBM, but to a lesser extent than AFF7010. The increased retention of BMP to the sponge is not seen by adding AFF2006, a BMP-binding peptide that does not contain a collagen-binding sequence.

[0092] To show that this effect is dose dependent not only on the amount of BMP put onto the sponge but also on the amount of IFBM present, a series of two-dimensional dose response curves was obtained in which the concentrations of both the IFBM and BMP were varied. These results are shown in the FIGS. 6A-6D and demonstrate that the binding of BMP to the collagen sponge is dependent on both BMP concentration and IFBM concentration. Increasing the concentration of the IFBM (AFF7005, AFF7006, AFF7009, or AFF7010) leads to a larger amount of BMP-2 that is retained on the collagen.

Example 5

Peptides that Bind to Stainless Steel

[0093] Selection of stainless steel-binding peptides was performed as described above for the titanium-binding peptides except that 5/32 inch stainless steel beads were used instead of titanium beads. The stainless steel binding peptides that were isolated are shown in Table 8. In some embodiments, an exemplary binding module of the invention comprises only that portion of the sequence shown in uppercase letters.

TABLE-US-00008 TABLE 8 Stainless Steel Binding Peptides Phage SEQ ID Designation Peptide Sequence NO: AP08-03 ssSSYFNLGLVKHNHVRHHDSsr 39 AP08-02 ssCHDHSNKYLKSWKHQQNCsr 40 AP08-01 ssSCKHDSEFIKKHVHAVKKCsr 41 AP08-04 ssSCHHLKHNTHKESKMHHECsr 42 AP08-06 ssVNKMNRLWEPLsr 43

Example 6

Peptides that Bind to Teflon

[0094] Selection of Teflon (GoreTex.RTM.; polytetrafuorethylene (PTFE))-binding peptides was performed as described above for the titanium-binding peptides except that sections of GoreTex fabric were used instead of titanium beads. The Teflon-binding peptides that were isolated are shown in Table 9. In some embodiments, an exemplary binding module of the invention comprises only that portion of the sequence shown in uppercase letters.

TABLE-US-00009 TABLE 9 Teflon Binding Peptides Clone SEQ. ID. Number Peptide Sequence NO.: AP16-01 ssCWSRFRLFMLFCMFYLVSsr 95 AP16-02 srCIKYPFLYCCLLSLFLFSsr 96

Example 7

Isolation of Peptides that Specifically Bind to BMPRI and/or BMPRII

[0095] Identification of peptides that bind to BMPRI and/or BMPRII: In order to identify peptides that specifically bind to Bone Morphogenic Protein Receptor I (BMPRIA) and/or Bone Morphogenic Protein Receptor II ("BMPRII"), phage display libraries are screened to identify phage encoding peptides that bind to the extracellular domains of each receptor. The extracellular domains of these receptors are known in the art (Rosenweig et al. (1995) Proc. Nat'l. Acad. Sci. USA 92: 7632-7636; Ten Dijke et al. (1994) J. Biol. Chem. 269: 16985-16988). Various phage libraries are screened. Where appropriate, a phage library can be selected that is designed around a specific amino acid motif or that was made with a particular amino acid bias. BMPRIA and BMPRII (R&D Systems, Cat. Nos. 315-BR/CF and 811-BR) are dissolved in carbonate coating buffer (100 mM NaHCO.sub.3, pH 9.6); 100 .mu.l of this solution is added to the wells of a 96-well Immulon.RTM.-4 microtiter plate (Dynex Technologies, Chantilly, Va.). The plate is incubated overnight at 4.degree. C. and then the nonspecific binding sites on the surface of the polystyrene are blocked with 1% Bovine Serum Albumin (BSA) in carbonate coating buffer. The plate is then incubated for an hour at room temperature with shaking at 50 rpm. The wells are then washed 5 times with 300 .mu.l of PBS-T (Sigma Chemical Co., St. Louis, Mo., Cat. #P-3563). Each library is diluted in PBS-T and added at a concentration of 1010 pfu/ml in a total volume of 100 ul. The plates are then incubated at room temperature with shaking at 50 rpm for 3 hours; unbound phage is then removed with 5 washes of PBS-T. Bound phage are recovered by denaturation with 0.1 M glycine buffer pH 2.2 (see Phage Display of Peptides and Proteins: A Laboratory Manual, 1996, eds. Kay et al. (Academic Press, San Diego, Calif.)). Eluted phage are neutralized with phosphate buffer and then added to E. coli DH5.alpha. cells in 2.times.YT media. This mixture is incubated overnight at 37.degree. C. in a shaker at 210 rpm. Phage supernatant is harvested by centrifuging at 8500.times.g for 10 minutes. Second and third rounds of selection are performed similarly to the first round of selection using the phage from the previous round of selection as the input phage. Phage display techniques are well known in the art, for example, as described in Sparks et al. (1996) "Screening phage-displayed random peptide libraries," pp. 227-253 in Phage Display of Peptides and Proteins: A Laboratory Manual, eds. Kay et al. (Academic Press, San Diego, Calif.).

[0096] To identify phage that specifically bind to BMPRIA or BMPRII, conventional ELISAs are performed using an anti-M13 phage antibody conjugated to horseradish peroxidase (HRP), followed by the addition of chromogenic agent ABTS (Sigma Chemical Co., St. Louis, Mo., Cat. #A3219). Relative binding strengths of the phage are determined by testing serial dilutions of the phage for binding to BMP receptors in an ELISA. The DNA encoding each selected peptide is isolated and sequenced to determine the amino acid sequence of the selected peptide.

[0097] These peptides are then linked together to create an analyte module that will bind to each of BMPRI and BMPRII, forming a heterodimer of these two receptors so as to induce signaling. Candidate peptides are synthesized and biotinylated and their binding to the BMP receptors confirmed. Briefly, the biotinylated peptides are synthesized with a linker between the BMP receptor binding sequence and the attached biotin moiety. This linker has the amino acid sequence GSSGK, which serves to separate the biotin moiety from the receptor binding portion of the peptide and which is flexible. Peptides are synthesized using solid-phase peptide synthetic techniques on a Rainin Symphony Peptide Synthesizer (Rainin Instrument Co., Emeryville, Calif.) using standard Fmoc chemistry. N-.alpha.-Fmoc-amino acids (with orthogonal side chain protecting groups) can be purchased from Novabiochem (Calbiochem-Novabiochem, Laufelfingen, Switzerland). After all residues are coupled, simultaneous cleavage and side chain deprotection will be achieved by treatment of a trifluoroacetic acid (TFA) cocktail. Crude peptide is precipitated with cold diethyl ether and purified by high-performance liquid chromatography on a Shimadzu Analytical/Semi-preparative HPLC unit on a Vydac C18 silica column (preparative 10 .mu.m, 250 mm.times.22 mm; Grace Vydac Co., Hesperia, Calif.) using a linear gradient of water/acetonitrile containing 0.1% TFA. Homogeneity of the synthetic peptides is evaluated by analytical RP-HPLC (Vydac C18 silica column, 10 .mu.m, 250 mm.times.4.6 mm) and the identity of the peptides is confirmed with MALDI-TOF-MS, for example, as performed commercially at the UNC-CH Proteomics Core Facility.

[0098] Generation of peptides that bind to BMPRI and/or BMPRII with high affinity: Peptides that are initially identified as binding to BMPRI and/or BMPRII may have low binding affinities, e.g., in the mid- to low-.mu.M range, whereas it may be preferable that peptides for use in an IFBM have higher binding affinities, e.g., in the nM range. To identify such peptides, libraries of variants of the initially identified peptides are constructed and screened by affinity selection against BMPRI and/or BMPRII.

[0099] Determination of binding affinity is evaluated using procedures known in the art. For example, BMPRI, BMPRII, and appropriate control proteins are dissolved in carbonate coating buffer (100 mM NaHCO.sub.3, pH 9.6) and added to the wells of a 96-well polypropylene plate. After incubation overnight at 4.degree. C., the wells are blocked with 1% BSA in PBS-T. Each receptor and control is tested for binding over a range of peptide concentrations from 0 to 200 .mu.M in sterile PBS (pH 7.2). The wells are then washed to remove unbound peptide and a streptavidin-alkaline phosphatase conjugate solution (SA-AP) from USB (United States Biochemical #11687) is added to each well to quantify the amount of bound peptide. Streptavidin-alkaline phosphatase activity is measured using the chromogenic reagent p-nitrophenyl phosphate reagent (Sigma-Aldrich, Inc., SigmaFast tablets, catalog #N1891) and measuring absorbance at 405 nm. To determine a binding curve and rough K.sub.D, absorbance is plotted as a function of the concentration for each peptide. The impact of other factors on binding can be assessed, such as for example, pH, temperature, salt concentration, buffer components, and incubation time.

[0100] To create and identify peptides that bind to BMPRI and/or BMPRII with higher affinity, phage libraries are created based on an amino acid motif identified among the initial peptides isolated as binding to BMPRI and/or BMPRII and screened further for peptides with improved binding properties. Such techniques are known in the art (see, for example, Hyde-DeRuyscher et al. (2000) Chem. Biol. 7: 17-25; Dalby et al. (2000) Protein Sci. 9: 2366-2376).

[0101] Characterization of agonist activity of hybrid peptides comprising BMPRI-binding peptides and BMPRII-binding peptides: Synthetic peptides are chemically synthesized that comprise both a BMPRI-binding peptide and a BMPRII-binding peptide connected with a flexible linker (e.g., a linker having the sequence GSSGSSG). Alternatively, the two receptor-binding peptides may be linked through the .alpha. and .epsilon. amino groups of a lysine (e.g., as in Cwirla et al. (1997) Science 276: 1696-1699 or in Wrighton et al. (1997) Nat. Biotechnol. 15: 1261-1265). These peptides are about 40 amino acids in length and are readily synthesized and purified.

[0102] These peptides are then assayed for BMP activity such as, for example, the induction of alkaline phosphatase activity in mouse mesenchymal C3H10T1/2 cells as known in the art and described, for example, by Cheng et al. (2003) J. Bone Joint Surg. Am. 85-A: 1544-1552 and Ruppert et al. (1996) Eur. J. Biochem. 237: 295-302. Briefly, C3H10T1/2 cells are added to a 96-well plate (3.times.10.sup.4 cells per well in a volume of 200 .mu.l) in Gibco.RTM. MEM/EBSS medium (Invitrogen Corp., Carlsbad, Calif., Cat #11095-080) with 10% FBS and appropriate antibiotics and antimycotics. Cells are permitted to adhere to the plate for at least 3 hours by incubating at 37.degree. C. in a 5% CO.sub.2 atmosphere. Media is then aseptically aspirated and BMP-2 or peptides are added at various concentrations in high-glucose Gibco.RTM. DMEM (Invitrogen Corp., Carlsbad, Calif., Cat. #11965-092) plus 2% FBS. Cells are incubated with the tested compounds for three days, at which time the media is aspirated and the cells are washed three times with 300 .mu.l of PBS (Gibco.RTM. PBS, Cat. #14190-144, Invitrogen Corp., Carlsbad, Calif.). 100 .mu.l of pNPP (p-Nitrophenyl Phosphate Sigma Fast Tablet Set Cat #N-1891) in H.sub.2O is added to each well and the color is allowed to develop for up to 18 hours at 37.degree. C. before absorbance is read at 405 nm.

[0103] EC.sub.50 values are then determined using methods known in the art. Typical EC.sub.50 values for this assay for BMP-2 range between 1 .mu.g/ml and 10 .mu.g/ml (see, e.g., Wiemann et al. (2002) J. Biomed. Mater. Res. 62: 119-127). It is known in the art that BMP-2 isolated from different sources can show different levels of activity, and one of skill in the art can adjust procedures accordingly to take these differences into account to achieve the desired result. For example, it is known in the art that recombinant human BMP-2 ("rhBMP-2") prepared using CHO cells has activity which differs 5-10 fold from the activity of recombinant human BMP-2 prepared using E. coli (see, e.g., Zhao and Chen (2002), "Expression of rhBMP-2 in Escherichia coli and Its Activity in Inducing Bone Formation," in Advances in Skeletal Reconstruction Using Bone Morphogenic Proteins, ed. T. S. Lindholm).

[0104] Immobilization of hybrid peptides onto collagen: Hybrid peptides that show BMP activity are synthetically linked to a peptide that binds to collagen. Briefly, a peptide containing the collagen binding module and the BMPRI-binding module is synthesized with an orthogonal protecting group on an amino acid in the linker between the modules, such as Fmoc-Lys(Dde)-OH. The Dde protecting group on the c amino group of the lysine side chain can be selectively removed and a BMPRII-binding peptide coupled to the c amino group. Alternatively, a linear peptide can be synthesized that comprises the collagen-binding module, the BMPRI-binding module, and the BMPRII-binding module.

[0105] The collagen-bound hybrid peptide is then tested for its BMP activity, such as by assaying for the induction of alkaline phosphatase activity in mouse mesenchymal C3H10T1/2 cells while the hybrid peptide is bound to a collagen matrix. Briefly, 5-mm disks of collagen are washed with PBS and added to the cell-based BMP activity assay.

Example 8

Sterilization of Surfaces Coated with IFBMs

[0106] IFBM-coated surfaces were treated with electron-beam sterilization procedures and gamma sterilization procedures. The binding performance of the coated surfaces was assessed before and after the sterilization procedures. Assays were performed on polystyrene and titanium surfaces. For the polystyrene assay, a binding module ("AFF-0002-PS") was biotinylated and relative binding was assessed by exposing the binding module to streptavidin-conjugated alkaline phosphatase. The results showed that the amount of biotinylated peptide that was bound to the polystyrene surface was essentially identical before and after the sterilization procedures. Similar results were obtained for an assay of a binding module ("AFF-0006-Ti") on titanium; in this assay, the performance of the coated surface before sterilization was approximately equal to its performance after sterilization.

Example 9

Preliminary Toxicity Testing

[0107] A PEGylated polystyrene-binding peptide was coated onto various polystyrene surfaces and tested as follows for adverse effects including cytotoxicity, hemolysis, and coagulation. The procedures were performed in Albino Swiss Mice (Mus musculus). As further discussed below, none of the IFBMs tested showed any signs of toxicity.

[0108] To assay for acute systemic toxicity, polystyrene squares (each square 4.times.4 cm; a total of 60 cm.sup.2) were incubated for 70-74 hours at 37.degree. C. in 20 mL of one of two vehicles: 0.9% USP normal saline or cotton seed oil (National Formulary). Five mice were each injected systemically with either vehicle or vehicle-extract at a dose rate of 50 mL extract per kg body weight. Mice were observed for signs of toxicity immediately after injection and at 4, 24, 48, and 72 hours post-injection. None of the animals injected with the vehicle-extract showed a greater biological reaction than those that received vehicle alone.

[0109] Coated surfaces were assayed for partial thromboblastin time according to ISO procedure 10993-4 (International Organization for Standardization, Geneva, Switzerland). Briefly, fresh whole human blood was drawn into vacutainer tubes containing sodium citrate and were spun down to isolate plasma, which was stored on ice until use. Coated polystyrene squares (as described above) were then incubated in the plasma at a ratio of 4 cm.sup.2 per 1 mL for 15 minutes at 37.degree. C. in polypropylene tubes and agitated at 60 rpm. The plasma extract was then separated, placed on ice, and tested on a Cascade.RTM. M-4 manual hemostasis analyzer (Helena Laboratories, Beaumont, Tex.). Clotting time was not significantly different than that observed for pure plasma or the standard reference control.

[0110] Cytotoxicity was assayed in L-929 Mouse Fibroblast Cells as specified in ISO 10993-5. Briefly, 60.8 cm.sup.2 of polystyrene-coated squares was extracted into 20.3 mL of Eagle's Minimum Essential Medium+5% FBS at 37.degree. C. for 24 hours. Positive, negative and intermediate cell-line test dishes were incubated at 37.degree. C. in a humidified 5% CO.sub.2 atmosphere. Cultures were evaluated for cytotoxic effects by microscopic observation at 24, 48, and 72 hours. The positive control showed a strong cytotoxic reaction score of "4" while test cells maintained a healthy ("0" score) appearance across all time points (score of "0"). Intermediate control cells scored as "2" across all time points.

[0111] Hemolysis testing measures the ability of a material or material extract to cause red blood cells to rupture. The test performed was ASTM F-756 Direct Contact Method. Saline was used to extract leachable substances. Coated polystyrene surface was extracted and then added to citrated rabbit blood (3.2%, diluted with PBS to obtain a total blood hemoglobin concentration of 10 mg/ml). A score of 0.4% was observed which falls into the passing category of 0-2%. The negative control returned a score of 0.1% and the positive control returned a score of 12.2%.

Sequence CWU 1

558117PRTArtificial Sequenceisolated from phage display libraries 1Ser Ser His Lys His Pro Val Thr Pro Arg Phe Phe Val Val Glu Ser1 5 10 15Arg222PRTArtificial Sequenceisolated from phage display libraries 2Ser Ser Cys Asn Cys Tyr Val Thr Pro Asn Leu Leu Lys His Lys Cys1 5 10 15Tyr Lys Ile Cys Ser Arg 20322PRTArtificial Sequenceisolated from phage display libraries 3Ser Ser Cys Ser His Asn His His Lys Leu Thr Ala Lys His Gln Val1 5 10 15Ala His Lys Cys Ser Arg 20422PRTArtificial Sequenceisolated from phage display libraries 4Ser Ser Cys Asp Gln Asn Asp Ile Phe Tyr Thr Ser Lys Lys Ser His1 5 10 15Lys Ser His Cys Ser Arg 20522PRTArtificial Sequenceisolated from phage display libraries 5Ser Ser Ser Ser Asp Val Tyr Leu Val Ser His Lys His His Leu Thr1 5 10 15Arg His Asn Ser Ser Arg 20622PRTArtificial Sequenceisolated from phage display libraries 6Ser Ser Ser Asp Lys Cys His Lys His Trp Tyr Cys Tyr Glu Ser Lys1 5 10 15Tyr Gly Gly Ser Ser Arg 20714PRTArtificial Sequenceisolated from phage display libraries 7His His Lys Leu Lys His Gln Met Leu His Leu Asn Gly Gly1 5 10814PRTArtificial Sequenceisolated from phage display libraries 8Gly His His His Lys Lys Asp Gln Leu Pro Gln Leu Gly Gly1 5 10925PRTArtificial Sequenceisolated from phage display libraries 9Ser Ser Ser Asp Lys Ser His Lys His Trp Tyr Ser Tyr Glu Ser Lys1 5 10 15Tyr Gly Gly Ser Gly Ser Ser Gly Lys 20 251025PRTArtificial Sequenceisolated from phage display libraries 10Ser Ser Ser Asp Lys Cys His Lys His Trp Tyr Cys Tyr Glu Ser Lys1 5 10 15Tyr Gly Gly Ser Gly Ser Ser Gly Lys 20 251121PRTArtificial Sequenceisolated from phage display libraries 11Ser Ser Asp Trp Gly Val Val Ala Ser Ala Trp Asp Ala Phe Glu Ala1 5 10 15Leu Asp Ala Ser Arg 201221PRTArtificial Sequenceisolated from phage display libraries 12Ser Ser Gly Ala Asp Phe Gly Tyr Gly Ser Trp Val Ser Phe Ser Ala1 5 10 15Leu Ser Ala Ser Arg 201321PRTArtificial Sequenceisolated from phage display libraries 13Ser Arg Gly Glu Ala Ser Gly Trp Glu Ala Phe Ser Ala Leu Glu Ala1 5 10 15Ala Val Val Ser Arg 201421PRTArtificial Sequenceisolated from phage display libraries 14Ser Arg Ser Ser Asp Ser Ala Phe Ser Ser Phe Ser Ala Leu Glu Gly1 5 10 15Ser Val Val Ser Arg 201521PRTArtificial Sequenceisolated from phage display libraries 15Ser Arg Asp Gly Ala Gly Ala Ala Ala Trp Gly Ala Phe Ser Ala Leu1 5 10 15Ala Ser Glu Ser Arg 201621PRTArtificial Sequenceisolated from phage display libraries 16Ser Arg Gly Gly Glu Ala Ala Ala Gly Ala Trp Val Ser Phe Ser Ala1 5 10 15Leu Glu Ser Ser Arg 201721PRTArtificial Sequenceisolated from phage display libraries 17Ser Arg Val Ser Gly Val Ala Ala Trp Glu Ala Phe Ala Gly Leu Ser1 5 10 15Val Ser Ser Ser Arg 201821PRTArtificial Sequenceisolated from phage display libraries 18Ser Arg Asp Gly Gly Ser Phe Ser Ala Phe Ser Ser Leu Val Trp Ala1 5 10 15Ala Asp Ser Ser Arg 201921PRTArtificial Sequenceisolated from phage display libraries 19Ser Ser Val Ala Gly Asp Val Gly Ser Ser Trp Ala Ala Phe Ala Ser1 5 10 15Leu Ala Ala Ser Arg 202021PRTArtificial Sequenceisolated from phage display libraries 20Ser Ser Trp Glu Val Phe Ser Ser Leu Glu Ser Gly Ser Val Gly Ala1 5 10 15Gly Ala Gly Ser Arg 202121PRTArtificial Sequenceisolated from phage display libraries 21Ser Ser Ser Ser Gly Ala Val Ser Ser Phe Glu Ser Leu Ser Gly Ser1 5 10 15Val Val Ser Ser Arg 202221PRTArtificial Sequenceisolated from phage display libraries 22Ser Arg Glu Gly Val Ala Trp Glu Ala Phe Gly Ala Leu Ser Ser Phe1 5 10 15Ala Ala Asp Ser Arg 202321PRTArtificial Sequenceisolated from phage display libraries 23Ser Ser Trp Gly Leu Ala Ser Glu Ala Ser Phe Phe Ser Phe Ser Ala1 5 10 15Leu Ser Ser Ser Arg 202421PRTArtificial Sequenceisolated from phage display libraries 24Ser Arg Glu Gly Ala Ala Trp Asp Ser Phe Phe Ala Leu Ser Gly Gly1 5 10 15Ser Ala Ala Ser Arg 202517PRTArtificial Sequenceisolated from phage display libraries 25Ser Ser Ser Val Asp Leu Tyr Phe Pro Leu Lys Gly Asp Val Val Ser1 5 10 15Arg 2617PRTArtificial Sequenceisolated from phage display libraries 26Ser Ser Phe Glu Pro Leu Arg Phe Pro Leu Lys Gly Val Pro Val Ser1 5 10 15Arg277PRTArtificial Sequenceconsensus sequence from comparing peptides isolated from phage display libraries 27Xaa Xaa Xaa Phe Xaa Xaa Leu1 5287PRTArtificial Sequenceconsensus sequence from comparing peptides isolated from phage display libraries 28Xaa Xaa Phe Pro Leu Xaa Gly1 52939PRTArtificial SequenceIFBM 29Ser Ser Phe Glu Pro Leu Arg Phe Pro Leu Lys Gly Val Pro Val Ser1 5 10 15Arg Gly Ser Ser Gly Lys Asp Val Asn Ser Ile Trp Met Ser Arg Val 20 25 30Ile Glu Trp Thr Tyr Asp Ser 353039PRTArtificial SequenceIFBM 30Asp Val Asn Ser Ile Trp Met Ser Arg Val Ile Glu Trp Thr Tyr Asp1 5 10 15Ser Gly Ser Ser Gly Lys Ser Ser Phe Glu Pro Leu Arg Phe Pro Leu 20 25 30Lys Gly Val Pro Val Ser Arg 353143PRTArtificial SequenceIFBM 31Ser Arg Ser Ser Asp Ser Ala Phe Ser Ser Phe Ser Ala Leu Glu Gly1 5 10 15Ser Val Val Ser Arg Gly Ser Ser Gly Lys Asp Val Asn Ser Ile Trp 20 25 30Met Ser Arg Val Ile Glu Trp Thr Tyr Asp Ser 35 403243PRTArtificial SequenceIFBM 32Asp Val Asn Ser Ile Trp Met Ser Arg Val Ile Glu Trp Thr Tyr Asp1 5 10 15Ser Gly Ser Ser Gly Lys Ser Arg Ser Ser Asp Ser Ala Phe Ser Ser 20 25 30Phe Ser Ala Leu Glu Gly Ser Val Val Ser Arg 35 403339PRTArtificial SequenceIFBM 33Ser Ser Ser Val Asp Leu Tyr Phe Pro Leu Lys Gly Asp Val Val Ser1 5 10 15Arg Gly Ser Ser Gly Lys Asp Val Asn Ser Ile Trp Met Ser Arg Val 20 25 30Ile Glu Trp Thr Tyr Asp Ser 353439PRTArtificial SequenceIFBM 34Asp Val Asn Ser Ile Trp Met Ser Arg Val Ile Glu Trp Thr Tyr Asp1 5 10 15Ser Gly Ser Ser Gly Lys Ser Ser Ser Val Asp Leu Tyr Phe Pro Leu 20 25 30Lys Gly Asp Val Val Ser Arg 353543PRTArtificial SequenceIFBM 35Ser Arg Gly Gly Glu Ala Ala Ala Gly Ala Trp Val Ser Phe Ser Ala1 5 10 15Leu Glu Ser Ser Arg Gly Ser Ser Gly Lys Asp Val Asn Ser Ile Trp 20 25 30Met Ser Arg Val Ile Glu Trp Thr Tyr Asp Ser 35 403643PRTArtificial SequenceIFBM 36Asp Val Asn Ser Ile Trp Met Ser Arg Val Ile Glu Trp Thr Tyr Asp1 5 10 15Ser Gly Ser Ser Gly Lys Ser Arg Gly Gly Glu Ala Ala Ala Gly Ala 20 25 30Trp Val Ser Phe Ser Ala Leu Glu Ser Ser Arg 35 403743PRTArtificial SequenceIFBM 37Ser Ser Asp Trp Gly Val Val Ala Ser Ala Trp Asp Ala Phe Glu Ala1 5 10 15Leu Asp Ala Ser Arg Gly Ser Ser Gly Lys Asp Val Asn Ser Ile Trp 20 25 30Met Ser Arg Val Ile Glu Trp Thr Tyr Asp Ser 35 403843PRTArtificial SequenceIFBM 38Asp Val Asn Ser Ile Trp Met Ser Arg Val Ile Glu Trp Thr Tyr Asp1 5 10 15Ser Gly Ser Ser Gly Lys Ser Ser Asp Trp Gly Val Val Ala Ser Ala 20 25 30Trp Asp Ala Phe Glu Ala Leu Asp Ala Ser Arg 35 403923PRTArtificial Sequenceisolated from phage display libraries 39Ser Ser Ser Ser Tyr Phe Asn Leu Gly Leu Val Lys His Asn His Val1 5 10 15Arg His His Asp Ser Ser Arg 204022PRTArtificial Sequenceisolated from phage display libraries 40Ser Ser Cys His Asp His Ser Asn Lys Tyr Leu Lys Ser Trp Lys His1 5 10 15Gln Gln Asn Cys Ser Arg 204123PRTArtificial Sequenceisolated from phage display libraries 41Ser Ser Ser Cys Lys His Asp Ser Glu Phe Ile Lys Lys His Val His1 5 10 15Ala Val Lys Lys Cys Ser Arg 204223PRTArtificial Sequenceisolated from phage display libraries 42Ser Ser Ser Cys His His Leu Lys His Asn Thr His Lys Glu Ser Lys1 5 10 15Met His His Glu Cys Ser Arg 204315PRTArtificial Sequenceisolated from phage display libraries 43Ser Ser Val Asn Lys Met Asn Arg Leu Trp Glu Pro Leu Ser Arg1 5 10 154421PRTArtificial Sequenceisolated from phage display libraries 44Ser Ser Ala Pro Leu Thr Glu Ser Glu Ala Trp Arg Gly Phe Ser Lys1 5 10 15Leu Glu Val Ser Arg 204521PRTArtificial Sequenceisolated from phage display libraries 45Ser Ser Ser Met Pro Val Gly Trp Asp Ser Trp Arg Gly Leu Glu Trp1 5 10 15Ser Asp Arg Ser Arg 204621PRTArtificial Sequenceisolated from phage display libraries 46Ser Ser Glu Gly Arg Gly Gly Trp Asn Ser Trp Glu Ala Phe Arg Glu1 5 10 15Leu Val Val Ser Arg 204721PRTArtificial Sequenceisolated from phage display libraries 47Ser Ser Gly Gly Gly Gly Ala Trp Glu Ser Trp Arg Gly Leu Ser Gly1 5 10 15Val Glu Leu Ser Arg 204821PRTArtificial Sequenceisolated from phage display libraries 48Ser Arg Asn Val Glu Gly Ser Trp Glu Ser Phe Ala Gly Leu Ser His1 5 10 15Val Arg Glu Ser Arg 204921PRTArtificial Sequenceisolated from phage display libraries 49Ser Arg Glu Asp Gly Gly Arg Trp Glu Ser Phe Leu Gly Leu Ser Ala1 5 10 15Val Glu Val Ser Arg 205021PRTArtificial Sequenceisolated from phage display libraries 50Ser Ser Val Glu Gly Ser Ala Trp Ser Ala Phe Lys Ser Leu Ser Ser1 5 10 15Glu Gly Val Ser Arg 205121PRTArtificial Sequenceisolated from phage display libraries 51Ser Arg Val Glu Gly Gly Ala Trp Gln Ala Leu Ala Gly Leu Thr Val1 5 10 15Glu Arg Val Ser Arg 205221PRTArtificial Sequenceisolated from phage display libraries 52Ser Ser Pro Pro Lys His Ala Trp Gly Ser Phe Asp Ala Leu Gly Gly1 5 10 15Gln Val Val Ser Arg 205321PRTArtificial Sequenceisolated from phage display libraries 53Ser Ser Glu Arg Gly Val Gly Trp Glu Val Phe Leu Ala Met Glu Gly1 5 10 15Ala Arg Met Ser Arg 205421PRTArtificial Sequenceisolated from phage display libraries 54Ser Ser Ser Ser Ser Gly Thr Trp Gln Ala Phe Thr Gly Leu Ser Gly1 5 10 15Glu Arg Val Ser Arg 205521PRTArtificial Sequenceisolated from phage display libraries 55Ser Ser Ser Pro Gly Gly Gly Ser Gly Gly Trp Asp Ala Phe Tyr Ser1 5 10 15Leu Val Gly Ser Arg 205621PRTArtificial Sequenceisolated from phage display libraries 56Ser Ser Gly Gly Gly Gly Gly Gly Glu Gly Phe Ser Ser Leu Ser Gly1 5 10 15Asn Gly Arg Ser Arg 205721PRTArtificial Sequenceisolated from phage display libraries 57Ser Ser Thr Gly Gly Gly Ser Trp Glu Glu Phe Lys Ala Met Thr Pro1 5 10 15Ser Trp Thr Ser Arg 205821PRTArtificial Sequenceisolated from phage display libraries 58Ser Ser Glu Gly Ser Gly Leu Trp Asp Ser Phe Ser Ser Leu Ser Val1 5 10 15His Glu Val Ser Arg 205921PRTArtificial Sequenceisolated from phage display libraries 59Ser Ser Gly Val Thr Gln Glu Ser Ala Ser Trp Ser Ser Phe Arg Thr1 5 10 15Leu Ala Val Ser Arg 206021PRTArtificial Sequenceisolated from phage display libraries 60Ser Ser Ser Lys Val Ala Pro Ser Gly Glu Trp Arg Ser Phe Ala Thr1 5 10 15Leu Glu Val Ser Arg 206121PRTArtificial Sequenceisolated from phage display libraries 61Ser Ser Glu Ala Gly Arg Gly Trp Glu Gly Phe Lys Ala Leu Glu Gly1 5 10 15Tyr Gln Val Ser Arg 206221PRTArtificial Sequenceisolated from phage display libraries 62Ser Ser Leu Gly Gln Thr Gly Trp Glu Ala Phe Glu Ser Leu Ser Gly1 5 10 15Thr Arg Gly Ser Arg 206321PRTArtificial Sequenceisolated from phage display libraries 63Ser Ser Val Ala Trp Asp Ala Phe Thr Val Phe Glu Ser Leu Glu Gly1 5 10 15Val Ala Thr Ser Arg 206421PRTArtificial Sequenceisolated from phage display libraries 64Ser Ser Glu Val Val Glu Pro Trp Glu Trp Trp Val Ala Leu Glu Arg1 5 10 15Ala Gly Gly Ser Arg 206521PRTArtificial Sequenceisolated from phage display libraries 65Ser Arg Val Ala Ala Val Ser Trp Glu Phe Phe Gly Ser Leu Ser Ser1 5 10 15Ala Gly Val Ser Arg 206621PRTArtificial Sequenceisolated from phage display libraries 66Ser Ser Ala Asp Leu Gly Val Ser Gly Ser Trp Glu Gly Phe Ala Leu1 5 10 15Met Arg Gly Ser Arg 206721PRTArtificial Sequenceisolated from phage display libraries 67Ser Ser Val Gly Gln Met Gly Trp Glu Ala Phe Glu Ser Leu Ser Gly1 5 10 15Thr Gly Gly Ser Arg 206821PRTArtificial Sequenceisolated from phage display libraries 68Ser Ser Gly Gln Gly Glu Thr Trp Glu Trp Phe Ala Gly Met Arg Gly1 5 10 15Ser Val Ala Ser Arg 206921PRTArtificial Sequenceisolated from phage display libraries 69Ser Ser Tyr Phe Asp Val Phe Ser Ser Met Thr Gly Thr Arg Ala Ala1 5 10 15Gly Ser Trp Ser Arg 207021PRTArtificial Sequenceisolated from phage display libraries 70Ser Ser Ala Tyr Ser Val Phe Ser Ser Leu Arg Ala Asp Asn Ser Gly1 5 10 15Gly Ala Val Ser Arg 207119PRTArtificial Sequenceisolated from phage display libraries 71Ser Ser Gly Gly Ile Ala Ser Leu Lys Tyr Asp Val Val Lys Thr Trp1 5 10 15Glu Ser Arg7216PRTArtificial Sequenceconsensus sequence from comparing peptides isolated from phage display libraries 72Gly Gly Gly Ala Trp Glu Ala Phe Ser Ser Leu Ser Gly Ser Arg Val1 5 10 15737PRTArtificial Sequenceconsensus sequence from comparing peptides isolated from phage display libraries 73Trp Xaa Xaa Phe Xaa Xaa Leu1 57415PRTArtificial Sequenceconsensus sequence from comparing peptides isolated from phage display libraries 74Ser Ser Gly Ala Trp Glu Ser Phe Ser Ser Leu Ser Gly Ser Ser1 5 10 157540DNAArtificial Sequenceencoding consensus sequence 75tcgagtggtg cttgggagtc tttttcgtca ctgagtggat 407640DNAArtificial Sequencepartial complement of SEQ ID NO75 76caccacgaac cctcagaaaa agcagtgact cacctagatc 407721PRTArtificial Sequenceisolated from phage display libraries 77Ser Ser Glu Gly Val Gly Gly Phe Pro Leu Lys Gly Ile Pro Gln Glu1 5 10 15Ala Trp Ala Ser Arg 207821PRTArtificial Sequenceisolated from phage display libraries 78Ser Ser Pro Ser Gly Val Val Phe Pro Leu Arg Gly Glu Leu Leu Gly1 5 10 15Val Xaa Lys Ser Arg 207921PRTArtificial Sequenceconsensus sequence from comparing peptides isolated from phage display libraries 79Ser Ser Gly Gly Phe Val Pro Phe Pro Leu Arg Gly Glu Val Trp Asp1 5 10 15Gly Val His Ser Arg 208021PRTArtificial Sequenceisolated from phage display libraries 80Ser Ser Glu Gly Ser Leu Ser Phe Pro Leu Lys Gly Gln Val Tyr Ser1 5

10 15Gly Trp Gly Ser Arg 208121PRTArtificial Sequenceisolated from phage display libraries 81Ser Ser Gly Lys Pro Leu Glu Phe Pro Leu Arg Gly Thr Leu Ala Glu1 5 10 15Trp Pro Val Ser Arg 208221PRTArtificial Sequenceisolated from phage display libraries 82Ser Arg Gly Glu Ala Leu Gly Phe Pro Leu Thr Gly Gln Leu Met Glu1 5 10 15Ala Ala Glu Ser Arg 208321PRTArtificial Sequenceisolated from phage display libraries 83Ser Ser Met Trp Asp Val Gly Phe Pro Leu Lys Gly Arg Trp Ile Asp1 5 10 15Gly Ala Asp Ser Arg 208421PRTArtificial Sequenceisolated from phage display libraries 84Ser Ser Ser Asn Ser Leu Trp Phe Pro Leu Arg Gly Ser Thr Val Glu1 5 10 15Val Gly Ala Ser Arg 208521PRTArtificial Sequenceisolated from phage display libraries 85Ser Ser Gly Pro Ala Leu Arg Leu Pro Leu Arg Gly Thr Val Val Ser1 5 10 15Asp Val Pro Ser Arg 208621PRTArtificial Sequenceisolated from phage display libraries 86Ser Ser Ala Asp Arg Val Ala Trp Pro Leu Lys Gly Ala Pro Val Trp1 5 10 15Val Lys Glu Ser Arg 208721PRTArtificial Sequenceisolated from phage display libraries 87Ser Ser Gly Leu Ala Leu Gly Leu Pro Ile Lys Gly Trp Thr Val Ser1 5 10 15Gly Lys Asp Ser Arg 208821PRTArtificial Sequenceisolated from phage display libraries 88Ser Ser Gly Tyr Thr Leu Gly Phe Pro Leu Ser Gly Gln Thr Ile Lys1 5 10 15Asp Trp Pro Ser Arg 208921PRTArtificial Sequenceisolated from phage display libraries 89Ser Ser Glu Gly Trp Val His Phe Pro Leu Lys Gly Asp Val Met Gly1 5 10 15Gly Pro Phe Ser Arg 209021PRTArtificial Sequenceisolated from phage display libraries 90Ser Ser Gly Arg Tyr Val Ser Leu Pro Leu Lys Gly Glu Val Val Pro1 5 10 15Gln Thr Ala Ser Arg 209121PRTArtificial Sequenceisolated from phage display libraries 91Ser Ser Glu Gly Gly Val Gly Phe Pro Leu Lys Gly Ile Pro Gln Glu1 5 10 15Ala Trp Ala Ser Arg 209221PRTArtificial Sequenceisolated from phage display libraries 92Ser Arg Val Asp Ser Val Asn Phe Pro Leu Arg Gly Glu Thr Val Thr1 5 10 15Ser Met Val Ser Arg 209317PRTArtificial Sequenceconsensus sequence from comparing peptides isolated from phage display libraries 93Gly Gly Ala Leu Gly Phe Pro Leu Lys Gly Glu Val Val Glu Gly Trp1 5 10 15Ala947PRTArtificial Sequenceconsensus sequence from comparing peptides isolated from phage display libraries 94Leu Xaa Phe Pro Leu Lys Gly1 59522PRTArtificial Sequenceisolated from phage display libraries 95Ser Ser Cys Trp Ser Arg Phe Arg Leu Phe Met Leu Phe Cys Met Phe1 5 10 15Tyr Leu Val Ser Ser Arg 209622PRTArtificial Sequenceisolated from phage display libraries 96Ser Arg Cys Ile Lys Tyr Pro Phe Leu Tyr Cys Cys Leu Leu Ser Leu1 5 10 15Phe Leu Phe Ser Ser Arg 209718PRTArtificial Sequenceisolated from phage display libraries 97Cys Ala Glu Lys Trp Trp Trp Trp Ile Gln Tyr Ala Trp Gly Gly Val1 5 10 15Leu Cys9818PRTArtificial Sequenceisolated from phage display libraries 98Cys Asp Asp Ile Asp Tyr Ile Lys Glu Ala Pro Ile Asp Ala Met Met1 5 10 15Cys Cys9918PRTArtificial Sequenceisolated from phage display libraries 99Cys Asp Phe Phe Asn Arg His Gly Tyr Asn Ser Gly Cys Glu His Ser1 5 10 15Val Cys10018PRTArtificial Sequenceisolated from phage display libraries 100Cys Asp Phe His Ser Asn Lys Tyr Tyr Ile Asn Gln Ile Ala Gly Ser1 5 10 15Asp Cys10118PRTArtificial Sequenceisolated from phage display libraries 101Cys Asp Asn Gly Leu Asp Asp Cys Phe Glu Pro Cys Tyr Trp Ile Gln1 5 10 15Leu Cys10218PRTArtificial Sequenceisolated from phage display libraries 102Cys Phe Glu Ile Ser Ser Ser Ser Thr Pro Ile Glu Leu Trp Glu Ser1 5 10 15Val Cys10318PRTArtificial Sequenceisolated from phage display libraries 103Cys Phe Glu Ser Asp Phe Pro Asn Val Arg His His Val Leu Lys Gln1 5 10 15Ser Cys10418PRTArtificial Sequenceisolated from phage display libraries 104Cys Phe Phe Phe Arg Arg Gln Ile Glu Ile Tyr Tyr Ala Arg Phe Gly1 5 10 15Phe Cys10518PRTArtificial Sequenceisolated from phage display libraries 105Cys Phe Leu Phe Phe Ser Met Cys Asn Met Ala Cys Thr Lys Ala Lys1 5 10 15Glu Cys10618PRTArtificial Sequenceisolated from phage display libraries 106Cys Phe Tyr Gln Asn Val Ile Ser Ser Ser Phe Ala Gly Asn Pro Trp1 5 10 15Glu Cys 10718PRTArtificial Sequenceisolated from phage display libraries 107Cys Gly Asp His Met Thr Asp Lys Asn Met Pro Asn Ser Gly Ile Ser1 5 10 15Gly Cys10818PRTArtificial Sequenceisolated from phage display libraries 108Cys His Arg Tyr Asp Arg Arg Trp Thr Met Tyr Thr Arg Ala Arg Leu1 5 10 15Arg Cys10918PRTArtificial Sequenceisolated from phage display libraries 109Cys Ile Met Thr Ser Asp Met Val Asn Ala Ala Ile Trp Asn Glu Val1 5 10 15Gln Cys11018PRTArtificial Sequenceisolated from phage display libraries 110Cys Leu Phe Phe Phe Ser Met Ile Met Asn Phe Asp Phe Pro Asn Phe1 5 10 15Glu Cys11118PRTArtificial Sequenceisolated from phage display libraries 111Cys Leu Pro Pro Pro Tyr Glu Pro Lys Gln Leu Ala Glu Pro Cys Asp1 5 10 15Gly Cys11218PRTArtificial Sequenceisolated from phage display libraries 112Cys Leu Pro Trp Tyr Tyr Tyr Tyr Lys Ala Gln Gln Leu Tyr Asp His1 5 10 15Tyr Cys11318PRTArtificial Sequenceisolated from phage display libraries 113Cys Met Arg Arg Trp Asp Arg Trp Val Arg Trp Ala Trp Ser Arg Gln1 5 10 15Lys Cys11418PRTArtificial Sequenceisolated from phage display libraries 114Cys Met Trp Trp Trp Gln Trp Gly Ser Tyr Ile Tyr Gly Glu Leu Trp1 5 10 15Ile Cys11518PRTArtificial Sequenceisolated from phage display libraries 115Cys Asn Glu Asp Val Asn Asn Phe Pro Pro Arg Met Asn Thr Glu Leu1 5 10 15Gly Cys11618PRTArtificial Sequenceisolated from phage display libraries 116Cys Asn Met Leu Leu Asn Ser Leu Pro Leu Pro Ser Glu Asp Trp Ser1 5 10 15Ala Cys11718PRTArtificial Sequenceisolated from phage display libraries 117Cys Asn Asn Asn His Arg Asp Val Asn Trp Asn Leu Arg Asp Asn Thr1 5 10 15Ala Cys11818PRTArtificial Sequenceisolated from phage display libraries 118Cys Asn Asn Asn Val Asn Trp Tyr His Tyr Met Phe Ile Pro Trp Ala1 5 10 15Lys Cys11918PRTArtificial Sequenceisolated from phage display libraries 119Cys Asn Asn Val Asn Ala Cys Gln Asn His Glu Asn Asn Met His Asn1 5 10 15Asp Cys12018PRTArtificial Sequenceisolated from phage display libraries 120Cys Asn Pro Gly Tyr Asn Asn Met Met Asn Asp Ser Met Val Met Trp1 5 10 15Arg Cys12118PRTArtificial Sequenceisolated from phage display libraries 121Cys Pro Phe Thr His Ser Leu Ala Leu Asn Thr Asp Arg Ala Ser Pro1 5 10 15Gly Cys12218PRTArtificial Sequenceisolated from phage display libraries 122Cys Pro His Trp Pro Pro Pro Trp Cys Glu Trp Tyr Pro Glu Asn Trp1 5 10 15Cys Cys12318PRTArtificial Sequenceisolated from phage display libraries 123Cys Pro Asn Pro Phe Pro Glu Pro Leu Asn His Asp Ala Ile Asp Trp1 5 10 15Cys Cys12418PRTArtificial Sequenceisolated from phage display libraries 124Cys Pro Asn Val Pro Arg Pro Ala Gln Leu Ser Ile Cys Gly Asn Leu1 5 10 15Pro Cys12518PRTArtificial Sequenceisolated from phage display libraries 125Cys Pro Pro Met Tyr Pro Gln Trp Glu Gly Asp Pro Asn Gln Arg Tyr1 5 10 15Asp Cys12618PRTArtificial Sequenceisolated from phage display libraries 126Cys Pro Pro Pro Gly Gln Val Pro Pro Trp Pro Pro Ser Pro Pro Pro1 5 10 15Pro Cys12718PRTArtificial Sequenceisolated from phage display libraries 127Cys Pro Arg Arg His Lys Arg Tyr Asn Trp Phe Ala His Asn Ala Arg1 5 10 15Met Cys12818PRTArtificial Sequenceisolated from phage display libraries 128Cys Arg Gln Tyr Arg Phe Arg Pro Ile Val Arg Ala Arg Arg Leu Asn1 5 10 15Lys Cys12918PRTArtificial Sequenceisolated from phage display libraries 129Cys Arg Arg Phe Arg Ser Arg Cys Pro Gly Glu Trp Arg Ser Trp Thr1 5 10 15Thr Cys13018PRTArtificial Sequenceisolated from phage display libraries 130Cys Arg Val Gly Val Arg Arg Lys Glu Gly Gly Phe Arg Pro Trp Tyr1 5 10 15Lys Cys13118PRTArtificial Sequenceisolated from phage display libraries 131Cys Arg Val Arg Arg Glu Pro Arg Met Arg Lys Ile Lys Lys Met Ala1 5 10 15Leu Cys13218PRTArtificial Sequenceisolated from phage display libraries 132Cys Arg Tyr Ser Thr Ser Ser Trp Ser Asp Met Thr Cys Gly Cys Gly1 5 10 15Gln Cys13318PRTArtificial Sequenceisolated from phage display libraries 133Cys Ser Gly Trp Lys Trp Trp Val Phe His Val Cys Trp Lys Gln Val1 5 10 15His Cys13418PRTArtificial Sequenceisolated from phage display libraries 134Cys Ser Asn Ser Ser Cys Thr Ser His Thr Leu Tyr Ser Ser Val Met1 5 10 15Gly Cys13518PRTArtificial Sequenceisolated from phage display libraries 135Cys Ser Ser Phe Met Ser Met His His Trp His Val Val Val Asp Ser1 5 10 15Cys Cys13618PRTArtificial Sequenceisolated from phage display libraries 136Cys Ser Ser Ile Asn Ser Ser Tyr Val His Cys Leu Gly Cys Thr Glu1 5 10 15Ser Cys13718PRTArtificial Sequenceisolated from phage display libraries 137Cys Ser Ser Arg Tyr Ser Thr Ala Tyr His Met Ala Ser Asn Ser Ile1 5 10 15Phe Cys13818PRTArtificial Sequenceisolated from phage display libraries 138Cys Thr Glu Arg Arg Arg Arg Phe Asn Arg Asn Arg Pro Ala Lys Met1 5 10 15Arg Cys13918PRTArtificial Sequenceisolated from phage display libraries 139Cys Thr Pro Arg Pro Pro Val Pro Val Tyr Ile Pro Tyr Ser Ser Ser1 5 10 15Pro Cys14018PRTArtificial Sequenceisolated from phage display libraries 140Cys Val Asp Phe Lys Ser Lys Glu Lys Thr Glu Ile Met Leu Arg His1 5 10 15Ala Cys14118PRTArtificial Sequenceisolated from phage display libraries 141Cys Val Phe Asp Ser Lys His Phe Ser Pro Thr His Ser Pro His Asp1 5 10 15Val Cys14218PRTArtificial Sequenceisolated from phage display libraries 142Cys Val Tyr Lys Ile Tyr Tyr Leu Tyr Cys His Pro Tyr Leu Thr Phe1 5 10 15Pro Cys14318PRTArtificial Sequenceisolated from phage display libraries 143Cys Trp Lys Ser Ser Ser Ser Met Met Thr Ile Val Trp Trp Asn Lys1 5 10 15Met Cys14418PRTArtificial Sequenceisolated from phage display libraries 144Cys Trp Met Trp Trp Pro Glu Trp Trp Trp Gln Cys Ala Val Gln Cys1 5 10 15Asn Cys14518PRTArtificial Sequenceisolated from phage display libraries 145Cys Trp Tyr Thr Trp Trp Cys Gln Ala Ser Thr Met Gly Gln Ile Tyr1 5 10 15Glu Cys14618PRTArtificial Sequenceisolated from phage display libraries 146Cys Tyr Tyr Asp Ser Tyr Pro Ser Val Pro Tyr Tyr Tyr Gln Asn Pro1 5 10 15Ser Cys14718PRTArtificial Sequenceisolated from phage display libraries 147Cys Tyr Tyr Phe Tyr Gln Ala Leu Gln Gly Leu Ile Lys Asn His Trp1 5 10 15Ala Cys14818PRTArtificial Sequenceisolated from phage display libraries 148Cys Tyr Tyr Lys Pro Tyr Tyr Pro Cys Ser Ala Tyr Met Asn Phe Pro1 5 10 15Leu Cys14918PRTArtificial Sequenceisolated from phage display libraries 149Cys Tyr Tyr Asn Gly Leu Val Val His His Ser Asn Ser Gly His Lys1 5 10 15Asp Cys15017PRTArtificial Sequenceisolated from phage display libraries 150Cys Ala Asn Phe Leu Ser Phe Val Asn Asn Ser Tyr Cys Ile Asp Ser1 5 10 15Asn15117PRTArtificial Sequenceisolated from phage display libraries 151Cys Ala Arg Arg Arg His His His His Pro Pro Met Pro His Phe Arg1 5 10 15Arg15217PRTArtificial Sequenceisolated from phage display libraries 152Cys Cys Asp Gly Leu Ile Thr Ser Ser Trp Leu Asn Trp Phe Ala Arg1 5 10 15Gly15317PRTArtificial Sequenceisolated from phage display libraries 153Cys Cys Glu Trp Trp Trp Cys Trp Lys Trp Trp Gln Cys Leu Trp Trp1 5 10 15Cys15417PRTArtificial Sequenceisolated from phage display libraries 154Cys Cys Phe Asn Phe Phe Thr Ser Phe Asn Gln Gly Lys Asp Asn Phe1 5 10 15Val15517PRTArtificial Sequenceisolated from phage display libraries 155Cys Cys Ser Ser Cys Glu Ser His Trp Lys Lys Phe Glu His Asn Arg1 5 10 15Gln15617PRTArtificial Sequenceisolated from phage display libraries 156Cys Asp Asp Phe Val Leu Asp Tyr Asp Asp Glu Tyr Met Val Met Asn1 5 10 15His15717PRTArtificial Sequenceisolated from phage display libraries 157Cys Asp Asp Met Gly Asp Asp Val Lys Asp Pro Glu Asp Tyr Ile Asp1 5 10 15Gln15817PRTArtificial Sequenceisolated from phage display libraries 158Cys Asp Phe Cys Phe Thr Asn Val Leu Phe Asp Ala Phe Gly Ser His1 5 10 15Val15917PRTArtificial Sequenceisolated from phage display libraries 159Cys Asp Tyr Phe Ser Phe Leu Glu Cys Phe Ser Asn Gly Trp Ser Gly1 5 10 15Ala16017PRTArtificial Sequenceisolated from phage display libraries 160Cys Phe Phe Phe Gly Gln Gly Asp Phe Met Cys Trp Ile Cys Leu Thr1 5 10 15Val16117PRTArtificial Sequenceisolated from phage display libraries 161Cys Phe Phe Asn Ser Phe Asn Cys Thr Pro Asn Glu Met Trp Tyr Trp1 5 10 15Phe16217PRTArtificial Sequenceisolated from phage display libraries 162Cys Phe Phe Ser Tyr Cys Phe Ser His Asp Val Ser Thr Tyr Asn Thr1 5 10 15Ala16317PRTArtificial Sequenceisolated from phage display libraries 163Cys Phe Phe Ser Tyr Trp Asn Cys Leu Thr Asn Asn Ala Phe Val Lys1 5 10 15Pro16417PRTArtificial Sequenceisolated from phage display libraries 164Cys Phe Gly Phe Ser Asp Cys Leu Ser Trp Phe Val Gln Pro Ser Thr1 5 10 15Ala16517PRTArtificial Sequenceisolated from phage display libraries 165Cys Phe Gly Asn Phe Leu Ser Phe Gly Phe Asn Cys Glu Ser Ala Leu1 5 10 15Gly16617PRTArtificial Sequenceisolated from phage display libraries 166Cys Phe Gly Asn Leu Gly Asn Leu Ile Tyr Thr Cys Asp Arg Leu Met1 5 10 15Pro16717PRTArtificial Sequenceisolated from phage

display libraries 167Cys Phe Gly Asn Val Phe Cys Val Tyr Asn Gln Phe Ala Ala Gly Leu1 5 10 15Phe16817PRTArtificial Sequenceisolated from phage display libraries 168Cys Phe Thr Cys Phe Ser Phe Ala Phe Asn Phe Cys Phe Met Cys Trp1 5 10 15Met16917PRTArtificial Sequenceisolated from phage display libraries 169Cys Phe Thr Phe Phe Lys Ala Ser Trp Ser Trp Trp His His Ala Met1 5 10 15Met17017PRTArtificial Sequenceisolated from phage display libraries 170Cys Phe Val His Asn Phe Phe Trp Phe Leu Gly Lys Asn Ser Asn Cys1 5 10 15Arg17117PRTArtificial Sequenceisolated from phage display libraries 171Cys Phe Trp Tyr Ser Trp Leu Cys Ser Ala Ser Ser Ser Asp Ala Leu1 5 10 15Ile17217PRTArtificial Sequenceisolated from phage display libraries 172Cys Gly Tyr Phe Cys Ser Phe Tyr Asn Tyr Leu Asp Ile Gly Thr Ala1 5 10 15Ser17317PRTArtificial Sequenceisolated from phage display libraries 173Cys His Arg Cys Lys Arg Arg His Leu Leu Arg Arg Lys Gln Ala Asn1 5 10 15Arg17417PRTArtificial Sequenceisolated from phage display libraries 174Cys Ile Phe Asn Ser Tyr Phe Cys Ser Phe Gln Leu Thr Ser Tyr Gly1 5 10 15Ser17517PRTArtificial Sequenceisolated from phage display libraries 175Cys Lys Ala Phe Phe Phe Asn Phe Gln Cys Phe Val Phe Val Phe His1 5 10 15Phe17617PRTArtificial Sequenceisolated from phage display libraries 176Cys Lys Phe Ser Phe Asp Phe Phe Ala Arg Phe Asn Arg His Phe Tyr1 5 10 15His17717PRTArtificial Sequenceisolated from phage display libraries 177Cys Lys Ser Lys Lys Ser Ser His Ser Glu Ser Glu His Lys Lys Ser1 5 10 15Ser17817PRTArtificial Sequenceisolated from phage display libraries 178Cys Leu Phe Asn Cys Ser Gly Glu Ser Trp Pro Met Ser Ile Val Pro1 5 10 15Ser17917PRTArtificial Sequenceisolated from phage display libraries 179Cys Leu Lys Asp Tyr Tyr Tyr Ser Pro Cys Ser Tyr Ser Cys Asp Gln1 5 10 15His18017PRTArtificial Sequenceisolated from phage display libraries 180Cys Leu Leu Lys Tyr Cys Tyr Ser Asp Leu Ala Ser Ser Ser Leu Ser1 5 10 15Ile18117PRTArtificial Sequenceisolated from phage display libraries 181Cys Leu Val Phe Met Arg Pro Tyr Phe Leu Leu Val Phe Leu Met Cys1 5 10 15Trp18217PRTArtificial Sequenceisolated from phage display libraries 182Cys Leu Tyr Cys His Leu Asn Asn Gln Phe Leu Ser Trp Val Ser Gly1 5 10 15Asn18317PRTArtificial Sequenceisolated from phage display libraries 183Cys Leu Tyr Cys Leu Asn Tyr Ala Asn Phe Ser Asp Pro Met Thr Met1 5 10 15Phe18417PRTArtificial Sequenceisolated from phage display libraries 184Cys Asn His Leu Gly Phe Phe Ser Ser Phe Cys Asp Arg Leu Val Glu1 5 10 15Asn18517PRTArtificial Sequenceisolated from phage display libraries 185Cys Asn Ser Phe Met Phe Ile Asn Gly Ser Phe Lys Glu Thr Gly Gly1 5 10 15Cys18617PRTArtificial Sequenceisolated from phage display libraries 186Cys Asn Ser Ser Ser Tyr Ser Trp Tyr Cys Trp Phe Gly Gly Ser Ser1 5 10 15Pro18717PRTArtificial Sequenceisolated from phage display libraries 187Cys Arg Asp Arg Gln Arg Trp Val Arg Ile Phe Asn Arg Arg Cys Val1 5 10 15Thr18817PRTArtificial Sequenceisolated from phage display libraries 188Cys Arg Met Lys Lys Arg Arg Arg Ala His Pro Pro Arg Asn Cys Met1 5 10 15Glu18917PRTArtificial Sequenceisolated from phage display libraries 189Cys Arg Arg Met Arg Cys Arg Asp His Thr Gln Lys Trp Arg Arg Glu1 5 10 15Arg19017PRTArtificial Sequenceisolated from phage display libraries 190Cys Arg Arg Arg Lys Asn Phe Gln Arg Cys Phe Arg Pro Leu Leu Tyr1 5 10 15Pro19117PRTArtificial Sequenceisolated from phage display libraries 191Cys Arg Arg Arg Ser Gln Arg Arg Asn Arg Arg Gly Asn Asp Asp Ser1 5 10 15Ala19217PRTArtificial Sequenceisolated from phage display libraries 192Cys Ser Phe Phe Met Pro Trp Cys Asn Phe Leu Asn Gly Glu Met Ala1 5 10 15Val19317PRTArtificial Sequenceisolated from phage display libraries 193Cys Ser Phe Ser Val Ser Lys Ser Ser Gln Ile Phe Ala Val Ser Tyr1 5 10 15Ser19417PRTArtificial Sequenceisolated from phage display libraries 194Cys Ser Leu Thr Gly Cys Leu Tyr Asp Tyr Val Ser Phe Gly Trp Gly1 5 10 15Ala19517PRTArtificial Sequenceisolated from phage display libraries 195Cys Ser Ser Ser Met Thr Tyr Arg Thr Ser Ser Ser Trp His Leu Lys1 5 10 15Ile19617PRTArtificial Sequenceisolated from phage display libraries 196Cys Ser Thr Ser Tyr Ser Trp Asn Lys Trp Gln Ile Ser Ile Ser Ser1 5 10 15Tyr19717PRTArtificial Sequenceisolated from phage display libraries 197Cys Thr Cys Phe Asn Leu Phe Asp Met Lys Thr Cys Pro Ser Phe Cys1 5 10 15Thr19817PRTArtificial Sequenceisolated from phage display libraries 198Cys Thr Phe Gly Phe Pro Cys Val Met Ser Leu Val Asn His Val Pro1 5 10 15Ser19917PRTArtificial Sequenceisolated from phage display libraries 199Cys Thr Asn Ser Asn Leu Asn Ser Ser Ser Trp His Thr Met Val Asp1 5 10 15Arg20017PRTArtificial Sequenceisolated from phage display libraries 200Cys Thr Trp Trp Trp Trp Trp Val Val Asn Arg Glu Pro Tyr Val Ala1 5 10 15Cys20117PRTArtificial Sequenceisolated from phage display libraries 201Cys Trp Asp Trp Met Thr Trp Gly Asn Asp Val Leu Val Asn Thr Asp1 5 10 15Trp20217PRTArtificial Sequenceisolated from phage display libraries 202Cys Trp Leu Asp Asp Asp Ser Asp Asp Tyr Asp Asp Asp Asp Met Met1 5 10 15Ala20317PRTArtificial Sequenceisolated from phage display libraries 203Cys Trp Met Gly Leu Phe Glu Cys Pro Asp Ala Trp Leu His Asp Trp1 5 10 15Asp20417PRTArtificial Sequenceisolated from phage display libraries 204Cys Trp Asn Ile Ser Cys Met Phe Gly Phe Gly Trp Gly Gly Gly Gly1 5 10 15Leu20517PRTArtificial Sequenceisolated from phage display libraries 205Cys Tyr Ala Tyr Tyr Phe Phe Phe Tyr Ser Ser Gly Arg Gly Tyr His1 5 10 15Gln20617PRTArtificial Sequenceisolated from phage display libraries 206Cys Tyr Phe Pro Phe Tyr Cys Tyr Asn Thr Ser Ser Leu Ser Leu Asp1 5 10 15Phe20716PRTArtificial Sequenceisolated from phage display libraries 207Ala Asp Arg Val Trp Pro Arg His Thr Ser Ser Pro Tyr His Arg His1 5 10 1520816PRTArtificial Sequenceisolated from phage display libraries 208Ala Phe Ile Ser Asn Leu His Ala Ala Cys Ser Val Gly Ser Cys Lys1 5 10 1520916PRTArtificial Sequenceisolated from phage display libraries 209Cys His Thr Pro Trp Pro Pro Met Asn Arg Tyr Ala Ser Val Leu Ile1 5 10 1521016PRTArtificial Sequenceisolated from phage display libraries 210Cys Thr Arg Arg Arg Arg Phe Cys Val Ile Ile Phe Arg Arg Glu Met1 5 10 1521116PRTArtificial Sequenceisolated from phage display libraries 211Cys Thr Ser Ser Ser Gln Lys His Cys Tyr His Gly His Ser Ser Asp1 5 10 1521216PRTArtificial Sequenceisolated from phage display libraries 212Asp Cys Cys Cys Met Trp Asp Asp Gly Val Gly Asp Asp Val Asp Met1 5 10 1521316PRTArtificial Sequenceisolated from phage display libraries 213Asp Phe Cys Phe Met Met Met Asn Cys Thr Met Asn Ala His Tyr Phe1 5 10 1521416PRTArtificial Sequenceisolated from phage display libraries 214Asp Val Asn Ser Ile Trp Met Ser Arg Val Ile Glu Trp Thr Tyr Asp1 5 10 1521516PRTArtificial Sequenceisolated from phage display libraries 215Asp Trp Cys Asn Asn Ala Trp Asp Thr Tyr Ala Ile His Asn Asp Cys1 5 10 1521616PRTArtificial Sequenceisolated from phage display libraries 216Phe Leu Phe Phe Thr Asn Met Val Trp Tyr Phe Phe Ile Met Gly Ala1 5 10 1521716PRTArtificial Sequenceisolated from phage display libraries 217Phe Thr Val Ser Ser His Ile Ile Glu Trp Ser Ala Asp Ser Val Val1 5 10 1521816PRTArtificial Sequenceisolated from phage display libraries 218Gly Ala Gly Gly Phe Phe Leu Pro Cys Leu Trp Asn Pro Asp Arg Thr1 5 10 1521916PRTArtificial Sequenceisolated from phage display libraries 219Gly Lys Cys Val Phe Arg Arg Glu Asp Cys Phe Trp Tyr Tyr Met His1 5 10 1522016PRTArtificial Sequenceisolated from phage display libraries 220Gly Ser Ser Ser Cys Gln Gly Val Ser Gly Ser Asp Tyr Val Met Lys1 5 10 1522116PRTArtificial Sequenceisolated from phage display libraries 221His Ala Ser Ile His His Cys Ser Tyr Gln Gly Tyr Gly Gln Ser Gly1 5 10 1522216PRTArtificial Sequenceisolated from phage display libraries 222His Cys Asn Asn Glu Asn Arg Trp His His Asn Gly Ala Ile Gly Val1 5 10 1522316PRTArtificial Sequenceisolated from phage display libraries 223His Ile Ser Ser Cys Gln Met Val Gln Ser Trp Ser Arg Pro Ala His1 5 10 1522416PRTArtificial Sequenceisolated from phage display libraries 224Ile Trp Glu Trp Phe Glu Leu Glu Met Leu Tyr Val Asn Arg Tyr Cys1 5 10 1522516PRTArtificial Sequenceisolated from phage display libraries 225Leu Ile His Arg Tyr Cys Arg Arg Val Pro Cys Arg Arg Glu Leu Lys1 5 10 1522616PRTArtificial Sequenceisolated from phage display libraries 226Met Ser Asn Phe Leu Ile Glu Phe Thr Tyr Asp Asn Val Gly Val Arg1 5 10 1522716PRTArtificial Sequenceisolated from phage display libraries 227Asn Phe Phe Val Glu Trp Ala Phe Asp Thr Gln Asp Arg Glu Glu Leu1 5 10 1522816PRTArtificial Sequenceisolated from phage display libraries 228Asn Gly Asn Glu Asn Asp Thr Ile Asn Asp Asn Asp Ile Asn Ala Ser1 5 10 1522916PRTArtificial Sequenceisolated from phage display libraries 229Asn Ile Asn Ile Val Glu Glu Arg Phe Met Val Glu Trp Asp Val Gln1 5 10 1523016PRTArtificial Sequenceisolated from phage display libraries 230Asn Pro Trp Ala Ser Ser Leu Val Ala Ala Cys Tyr Leu Asp Glu Ser1 5 10 1523116PRTArtificial Sequenceisolated from phage display libraries 231Asn Trp Trp Met Val Asn Leu Ile Pro Asp Glu Trp Cys Trp Asn Ser1 5 10 1523216PRTArtificial Sequenceisolated from phage display libraries 232Pro Phe Leu Phe Glu Ala Ser Asp Arg His Pro Ala Phe Asn His Met1 5 10 1523316PRTArtificial Sequenceisolated from phage display libraries 233Pro Gly Ser Ser Thr Phe Tyr Ser Ile Thr Met Thr Trp Asp Leu Pro1 5 10 1523416PRTArtificial Sequenceisolated from phage display libraries 234Pro Pro Ser Ser Asn Ser Asn Phe Met Leu Glu Phe Ser Trp Asp Ser1 5 10 1523516PRTArtificial Sequenceisolated from phage display libraries 235Pro Gln Ser Glu His Ser Lys Ser Tyr Met Ser Trp Ala Arg Ser Ser1 5 10 1523616PRTArtificial Sequenceisolated from phage display libraries 236Pro Ser Ala Cys Ser Arg Arg Ile Ile Gln Asp Thr Phe Phe Phe Met1 5 10 1523716PRTArtificial Sequenceisolated from phage display libraries 237Gln Glu Leu Arg Val Arg Lys Arg Arg Arg Pro Lys Asp His Glu Arg1 5 10 1523816PRTArtificial Sequenceisolated from phage display libraries 238Gln Glu Met Leu Asn Phe Phe Phe His Asn Gly Asn Phe Phe Phe Val1 5 10 1523916PRTArtificial Sequenceisolated from phage display libraries 239Gln His Arg Gln His His Asn Val Ile Tyr Ser Ala Val Cys Val Ala1 5 10 1524016PRTArtificial Sequenceisolated from phage display libraries 240Gln Met Asp Thr Ile Asp Asp Met Thr Trp Thr Gly Asp Asp Asp Cys1 5 10 1524116PRTArtificial Sequenceisolated from phage display libraries 241Arg Gly Pro Tyr Ile Trp Trp Leu Glu Glu Gln Ser Arg Thr Trp Glu1 5 10 1524216PRTArtificial Sequenceisolated from phage display libraries 242Arg Arg Arg Asn Lys Leu Ala Arg Thr Leu Val Tyr Arg Arg Arg Val1 5 10 1524316PRTArtificial Sequenceisolated from phage display libraries 243Arg Arg Arg Pro Lys Pro Gly Pro His Ile Ile Phe Thr Ala Ile Asn1 5 10 1524416PRTArtificial Sequenceisolated from phage display libraries 244Arg Arg Tyr Ala Thr Trp Ser Val Ala Ser Ile Gln Glu Cys Pro Arg1 5 10 1524516PRTArtificial Sequenceisolated from phage display libraries 245Arg Tyr Pro Tyr Asp Met Asp Trp Asp Trp His His Gln Glu Arg Asp1 5 10 1524616PRTArtificial Sequenceisolated from phage display libraries 246Ser Phe Phe Phe Trp Asp Thr Phe Gly Glu Ser Asn Lys Phe Phe Met1 5 10 1524716PRTArtificial Sequenceisolated from phage display libraries 247Ser Phe Met Phe Asn Asp Ser Ile Asp Asp Asp Asp Asp Val Ser Glu1 5 10 1524816PRTArtificial Sequenceisolated from phage display libraries 248Ser Pro Gln Ala Arg Ser His Glu Asp Gln Val Met Gln Trp Trp Ile1 5 10 1524916PRTArtificial Sequenceisolated from phage display libraries 249Thr Phe Asp Asp Ala Met Leu Glu Trp Ser Leu Val Glu Trp Asp Ile1 5 10 1525016PRTArtificial Sequenceisolated from phage display libraries 250Thr Gly Gln Ser Ser Met Val Asn His Met Val Ser Glu Asn Gly Gly1 5 10 1525116PRTArtificial Sequenceisolated from phage display libraries 251Thr Met Gln Asp Phe Ser Ser Asp Glu Phe Tyr Thr Trp Thr Trp Asp1 5 10 1525216PRTArtificial Sequenceisolated from phage display libraries 252Val Phe Gly Phe Ser Cys Phe Glu Lys Asp Lys Arg Phe Asp Glu Leu1 5 10 1525316PRTArtificial Sequenceisolated from phage display libraries 253Val Leu Gly Trp Lys Ser Trp Lys Ile Tyr Trp Ala Trp Leu Val Glu1 5 10 1525416PRTArtificial Sequenceisolated from phage display libraries 254Trp Leu Trp Thr Trp Gln Glu Thr Ala Glu His Pro Ile Trp Asn Ser1 5 10 1525516PRTArtificial Sequenceisolated from phage display libraries 255Trp Met Trp Gln Ile Cys Pro Cys Met Met His Trp Val Leu Asn Trp1 5 10 1525616PRTArtificial Sequenceisolated from phage display libraries 256Trp Asn Cys Asp Tyr Glu Thr Gly Ala Gly Trp Arg Cys Ser Glu Ala1 5 10 1525716PRTArtificial Sequenceisolated from phage display libraries 257Trp Asn Phe Tyr Phe Val Ala Phe Ile Ala Leu Pro Met Glu Phe Val1 5 10 1525816PRTArtificial Sequenceisolated from phage display libraries 258Trp Trp Phe Arg Phe Lys Arg Arg Arg Arg Trp Met Lys Ser Val Arg1 5 10 1525916PRTArtificial Sequenceisolated from phage display libraries 259Tyr Asp Met Met Met Asp Met Leu Lys Asn Asp Asp Lys Gly Phe Phe1 5 10 1526016PRTArtificial Sequenceisolated from phage display libraries 260Tyr Arg Met Ala Asp Arg Asp Val His Arg Trp Asp Lys Glu Tyr Glu1 5 10 1526116PRTArtificial Sequenceisolated from phage display libraries 261Tyr

Arg Asn Met Glu Arg Ser Asn Met Ala Glu Thr Asn Ile Leu Ala1 5 10 1526216PRTArtificial Sequenceisolated from phage display libraries 262Tyr Tyr Phe Thr Glu Trp Ser Glu Asp Thr Ser Gly Gly Ser Ser Gly1 5 10 1526313PRTArtificial Sequenceisolated from phage display libraries 263Ala Lys Ile Leu Tyr Tyr Tyr Asp Met Gln Trp His Ile1 5 1026413PRTArtificial Sequenceisolated from phage display libraries 264Ala Pro Phe Leu Val Trp Tyr Ala Ser Thr Ser Asp Thr1 5 1026513PRTArtificial Sequenceisolated from phage display libraries 265Ala Val Ser Thr Ala Leu Tyr Asn Thr Trp Gln Val Leu1 5 1026613PRTArtificial Sequenceisolated from phage display libraries 266Cys Ala His Pro Pro Pro Tyr Lys Glu Asn Tyr Leu Tyr1 5 1026713PRTArtificial Sequenceisolated from phage display libraries 267Cys Cys Trp Thr Glu Ala Tyr Asp Ala His Pro Trp Arg1 5 1026813PRTArtificial Sequenceisolated from phage display libraries 268Cys Lys Phe Phe Phe His Tyr His Ile Gly Phe Ala Thr1 5 1026913PRTArtificial Sequenceisolated from phage display libraries 269Cys Val Trp Cys Ser Glu Tyr Phe Arg Glu Asp Pro Pro1 5 1027013PRTArtificial Sequenceisolated from phage display libraries 270Cys Tyr Thr Ser Lys Tyr Tyr Arg Glu Lys Tyr Glu Leu1 5 1027113PRTArtificial Sequenceisolated from phage display libraries 271Asp Thr Ile Trp Trp Trp Tyr Met Trp Cys Trp His Tyr1 5 1027213PRTArtificial Sequenceisolated from phage display libraries 272Glu His Gly Pro Phe Val Asp Ser Glu Tyr Pro Gln Pro1 5 1027313PRTArtificial Sequenceisolated from phage display libraries 273Phe Ala Asp Asn Leu Gly Tyr Val Gly Ser Asp Val Ile1 5 1027413PRTArtificial Sequenceisolated from phage display libraries 274Phe Ala Pro Met Lys Ser Tyr Gly Val Ser Leu Pro Pro1 5 1027513PRTArtificial Sequenceisolated from phage display libraries 275Phe Glu Leu Ala Thr Gly Tyr Val Pro Ala Leu Leu Lys1 5 1027613PRTArtificial Sequenceisolated from phage display libraries 276Phe Phe Phe Ser Met Ser Tyr Phe Phe Phe Arg Ala Ala1 5 1027713PRTArtificial Sequenceisolated from phage display libraries 277Phe Phe Gly Phe Asp Val Tyr Asp Met Ser Asn Ala Leu1 5 1027813PRTArtificial Sequenceisolated from phage display libraries 278Phe Phe His Phe Cys Phe Tyr Thr Cys Met Phe His Leu1 5 1027913PRTArtificial Sequenceisolated from phage display libraries 279Phe Phe Leu Ser Pro Phe Tyr Phe Phe Asn Glu Phe Phe1 5 1028013PRTArtificial Sequenceisolated from phage display libraries 280Phe Phe Met Ala Ser Ser Tyr Ser Tyr Pro Val Ala Gly1 5 1028113PRTArtificial Sequenceisolated from phage display libraries 281Phe Phe Pro Ser Ser Trp Tyr Ser His Leu Gly Val Leu1 5 1028213PRTArtificial Sequenceisolated from phage display libraries 282Phe Phe Val Leu Phe Leu Tyr Leu Trp Leu Gly Val Ser1 5 1028313PRTArtificial Sequenceisolated from phage display libraries 283Phe Gly Cys Glu Leu Pro Tyr Ser Gly Val Cys Ser Val1 5 1028413PRTArtificial Sequenceisolated from phage display libraries 284Phe Gly Ser Asp Val Phe Tyr Leu Arg Ser Ala Pro His1 5 1028513PRTArtificial Sequenceisolated from phage display libraries 285Phe His Glu Ala Pro Val Tyr Glu Thr Ser Glu Pro Pro1 5 1028613PRTArtificial Sequenceisolated from phage display libraries 286Phe Leu Gly Phe Gln Asp Tyr Lys Ser Ala Ala Met Met1 5 1028713PRTArtificial Sequenceisolated from phage display libraries 287Phe Leu Leu Thr Gly Glu Tyr Val Asp Val Val Ala Ala1 5 1028813PRTArtificial Sequenceisolated from phage display libraries 288Phe Leu Ser Phe Ala Asn Tyr Glu Asp Glu Leu Leu Arg1 5 1028913PRTArtificial Sequenceisolated from phage display libraries 289Phe Met Phe Ile Phe Phe Tyr Pro Val Phe Cys Phe Gln1 5 1029013PRTArtificial Sequenceisolated from phage display libraries 290Phe Arg Phe Phe Asn His Tyr Arg Tyr Pro Ser Gly Gln1 5 1029113PRTArtificial Sequenceisolated from phage display libraries 291Phe Arg Met Asp Phe Asp Tyr Leu Tyr Pro Ser Leu Pro1 5 1029213PRTArtificial Sequenceisolated from phage display libraries 292Phe Arg Tyr Phe Tyr Phe Tyr Ser His Gly Phe Lys Phe1 5 1029313PRTArtificial Sequenceisolated from phage display libraries 293Phe Ser Ala Leu Pro Thr Tyr Glu Val Asn Ser Tyr Lys1 5 1029413PRTArtificial Sequenceisolated from phage display libraries 294Phe Ser Asp Ser Ser Phe Tyr Ser Asp Leu Ser Val Val1 5 1029513PRTArtificial Sequenceisolated from phage display libraries 295Phe Ser Ser Val Asp Ser Tyr Ser Gly Pro Arg Pro Asp1 5 1029613PRTArtificial Sequenceisolated from phage display libraries 296Phe Ser Tyr Ser Val Ser Tyr Ala His Pro Glu Gly Leu1 5 1029713PRTArtificial Sequenceisolated from phage display libraries 297Phe Val Gly Phe Phe Leu Tyr Leu Thr Leu Leu Leu Pro1 5 1029813PRTArtificial Sequenceisolated from phage display libraries 298Gly Glu Asn Phe Cys Pro Tyr Ser Phe Phe Gly Cys Gly1 5 1029913PRTArtificial Sequenceisolated from phage display libraries 299Gly Phe Ala Trp Ser Ser Tyr Leu Gly Thr Thr Val His1 5 1030013PRTArtificial Sequenceisolated from phage display libraries 300Gly Phe Pro Phe Ile Phe Tyr Val Val Asp Trp Met Arg1 5 1030113PRTArtificial Sequenceisolated from phage display libraries 301Gly Phe Ser Glu Phe Leu Tyr Asp Leu Glu Val Gly Ile1 5 1030213PRTArtificial Sequenceisolated from phage display libraries 302Gly Phe Val Ala Tyr Asn Tyr Asp Lys Tyr Ser Gly Ala1 5 1030313PRTArtificial Sequenceisolated from phage display libraries 303Gly Val Ser Gln Phe Leu Tyr Asp Trp Val Lys Gly Gly1 5 1030413PRTArtificial Sequenceisolated from phage display libraries 304Gly Tyr Asn Ile Tyr Trp Tyr Ile Asn Asn Val Glu Tyr1 5 1030513PRTArtificial Sequenceisolated from phage display libraries 305His Tyr Lys Tyr Asn Val Tyr Cys Lys Tyr Asn Gly Tyr1 5 1030613PRTArtificial Sequenceisolated from phage display libraries 306Ile Phe Leu Pro Trp His Tyr Asp Gly Tyr Thr Phe Ala1 5 1030713PRTArtificial Sequenceisolated from phage display libraries 307Ile Phe Ser Phe Leu Ser Tyr Val Pro Val Asp Lys Val1 5 1030813PRTArtificial Sequenceisolated from phage display libraries 308Ile Tyr Ala Ala Leu Tyr Tyr Arg Phe Pro Thr Met Asp1 5 1030913PRTArtificial Sequenceisolated from phage display libraries 309Lys Phe Phe Phe Trp Phe Tyr Ile Asn Phe Val Met Met1 5 1031013PRTArtificial Sequenceisolated from phage display libraries 310Leu Asp Pro Leu Val Pro Tyr Leu Tyr Glu Asn Leu Phe1 5 1031113PRTArtificial Sequenceisolated from phage display libraries 311Leu Phe Asp Ala Tyr Trp Tyr Ser Asp Thr Ala Met Ser1 5 1031213PRTArtificial Sequenceisolated from phage display libraries 312Leu Leu Phe Phe Asp Asp Tyr Phe Lys Ser Ala Gly Arg1 5 1031313PRTArtificial Sequenceisolated from phage display libraries 313Leu Asn Phe Met Ile Phe Tyr Leu Ser Leu Asn Pro Trp1 5 1031413PRTArtificial Sequenceisolated from phage display libraries 314Leu Pro His Leu Ile Gln Tyr Arg Val Leu Leu Val Ser1 5 1031513PRTArtificial Sequenceisolated from phage display libraries 315Leu Pro Ser Gln Phe Gly Tyr Gly Ser Val Pro Thr Asp1 5 1031613PRTArtificial Sequenceisolated from phage display libraries 316Leu Pro Ser Gln Phe Gly Tyr Gly Ser Val Pro Thr Asp1 5 1031713PRTArtificial Sequenceisolated from phage display libraries 317Leu Ser Phe Ser Asp Phe Tyr Phe Ser Glu Gly Ser Glu1 5 1031813PRTArtificial Sequenceisolated from phage display libraries 318Leu Thr Asn Ser Gly Val Tyr Asp Gly Thr Pro Leu Pro1 5 1031913PRTArtificial Sequenceisolated from phage display libraries 319Leu Val Leu Leu Ile Leu Tyr Leu Phe Leu Ser Trp Pro1 5 1032013PRTArtificial Sequenceisolated from phage display libraries 320Leu Val Leu Leu Leu Phe Tyr Phe Leu Met Leu Ser Pro1 5 1032113PRTArtificial Sequenceisolated from phage display libraries 321Leu Tyr Leu Phe Tyr Pro Tyr Pro Asn Tyr Tyr Met Val1 5 1032213PRTArtificial Sequenceisolated from phage display libraries 322Asn Phe Ser Ser Ser Phe Tyr Ser Leu Val Ser Glu Gly1 5 1032313PRTArtificial Sequenceisolated from phage display libraries 323Asn Trp Tyr Ala Glu Tyr Tyr Tyr Val Tyr Asp Lys Gly1 5 1032413PRTArtificial Sequenceisolated from phage display libraries 324Asn Tyr Phe Ser Ala Met Tyr Tyr Asp Gly Trp Met Ser1 5 1032513PRTArtificial Sequenceisolated from phage display libraries 325Pro Ala Ser Leu Glu Leu Tyr Glu Asn Leu Val Ala Gly1 5 1032613PRTArtificial Sequenceisolated from phage display libraries 326Pro Cys Trp Tyr Arg Tyr Tyr His Glu Phe Trp Ile Trp1 5 1032713PRTArtificial Sequenceisolated from phage display libraries 327Pro Leu Tyr Tyr Glu Ser Tyr Arg Met Arg Thr Tyr Gln1 5 1032813PRTArtificial Sequenceisolated from phage display libraries 328Gln Tyr Ala Ser Tyr Met Tyr Tyr Cys Phe Pro Lys Tyr1 5 1032913PRTArtificial Sequenceisolated from phage display libraries 329Arg Ala Trp Trp Trp Trp Tyr Leu Asp Met Tyr Trp Thr1 5 1033013PRTArtificial Sequenceisolated from phage display libraries 330Arg Ala Tyr Asn Tyr Tyr Tyr Tyr Val Met Tyr Ala Cys1 5 1033113PRTArtificial Sequenceisolated from phage display libraries 331Arg Trp Ile Trp Trp Pro Tyr Val Asn Met Ile Trp Thr1 5 1033213PRTArtificial Sequenceisolated from phage display libraries 332Ser Asp Phe Leu Ser Pro Tyr Leu Ala Tyr Glu Arg Ser1 5 1033313PRTArtificial Sequenceisolated from phage display libraries 333Ser Phe Asp Val Arg Ser Tyr Val Leu Ala Gly Thr Glu1 5 1033413PRTArtificial Sequenceisolated from phage display libraries 334Ser Leu Phe Leu Asp Asp Tyr Ala Leu Gly Pro Arg Val1 5 1033513PRTArtificial Sequenceisolated from phage display libraries 335Ser Ser Val Leu Gly Phe Tyr Asp Pro Val Glu Val Ser1 5 1033613PRTArtificial Sequenceisolated from phage display libraries 336Ser Val Ala Phe Tyr Asp Tyr Leu Pro Thr Asp Leu Pro1 5 1033713PRTArtificial Sequenceisolated from phage display libraries 337Ser Val Leu Asp Phe Asn Tyr Gly His Asp Val Asn Val1 5 1033813PRTArtificial Sequenceisolated from phage display libraries 338Ser Val Ser Asp Phe Leu Tyr Arg Ser Ile Tyr Ser Leu1 5 1033913PRTArtificial Sequenceisolated from phage display libraries 339Ser Val Ser Asp Phe Leu Tyr Arg Ser Ile Tyr Ser Leu1 5 1034013PRTArtificial Sequenceisolated from phage display libraries 340Ser Val Ser Asp Phe Leu Tyr Arg Ser Ile Tyr Ser Leu1 5 1034113PRTArtificial Sequenceisolated from phage display libraries 341Ser Trp Ser Trp Trp Arg Tyr Gly Pro Gln Asn Thr Val1 5 1034213PRTArtificial Sequenceisolated from phage display libraries 342Ser Tyr Gly Phe Pro Ile Tyr Asp Ala Leu Leu Glu Gln1 5 1034313PRTArtificial Sequenceisolated from phage display libraries 343Val Phe Asp Val Gly Leu Tyr Trp His Ala Ala Pro Pro1 5 1034413PRTArtificial Sequenceisolated from phage display libraries 344Val Gly Phe Trp Val Asp Tyr Asp Asn Ser Ser Val Met1 5 1034513PRTArtificial Sequenceisolated from phage display libraries 345Val Leu Asp Leu Pro Tyr Tyr Trp Pro Val Lys Tyr Thr1 5 1034613PRTArtificial Sequenceisolated from phage display libraries 346Val Leu Leu Ala Asp Ser Tyr Gln Arg Asp Glu His Met1 5 1034713PRTArtificial Sequenceisolated from phage display libraries 347Val Leu Leu Phe Asp Asp Tyr Gly Tyr Ala Glu Ser Ala1 5 1034813PRTArtificial Sequenceisolated from phage display libraries 348Val Ser Ala Ser Gly Met Tyr Asp Gly Val Asp Leu Met1 5 1034913PRTArtificial Sequenceisolated from phage display libraries 349Val Ser Leu Leu Phe Ser Tyr Ser Pro Ala Gly Tyr Asp1 5 1035013PRTArtificial Sequenceisolated from phage display libraries 350Val Ser Ser Glu Trp Thr Tyr Gly Ala Val Ala Asp Leu1 5 1035113PRTArtificial Sequenceisolated from phage display libraries 351Val Ser Val Leu Ser Asp Tyr Ser Ile Lys Ala Leu Leu1 5 1035213PRTArtificial Sequenceisolated from phage display libraries 352Trp Ala Asp Met Tyr Tyr Tyr Tyr Asp Trp Tyr Thr Met1 5 1035313PRTArtificial Sequenceisolated from phage display libraries 353Trp Asp Trp Trp Gln Phe Tyr Glu Lys Met Trp Leu Phe1 5 1035413PRTArtificial Sequenceisolated from phage display libraries 354Trp Asn Trp Trp Gly Val Tyr Leu Gly Ile Cys Trp Leu1 5 1035513PRTArtificial Sequenceisolated from phage display libraries 355Trp Trp Gln Thr Trp Trp Tyr Arg Thr Tyr Trp Glu Ile1 5 1035613PRTArtificial Sequenceisolated from phage display libraries 356Tyr Ala Gly Val Tyr Ser Tyr Phe Thr Gly Ser Thr Leu1 5 1035713PRTArtificial Sequenceisolated from phage display libraries 357Tyr Cys Gln Tyr Arg Glu Tyr Tyr Thr Met Tyr Val Cys1 5 1035813PRTArtificial Sequenceisolated from phage display libraries 358Tyr Phe Val Glu Thr Tyr Tyr Asn Arg Tyr His Val Ser1 5 1035913PRTArtificial Sequenceisolated from phage display libraries 359Tyr Leu Ser Leu His Ala Tyr Glu Ser Phe Gly Gly Ser1 5 1036013PRTArtificial Sequenceisolated from phage display libraries 360Tyr Arg Tyr Gln Met Ser Tyr Tyr Ala Tyr Gln Tyr His1 5 1036113PRTArtificial Sequenceisolated from phage display libraries 361Tyr Ser Met Tyr Pro Ile Tyr Asn Lys Cys Ser Gln His1 5 1036213PRTArtificial Sequenceisolated from phage display libraries 362Tyr Trp Ile Tyr Asn Asn Tyr Thr Tyr Tyr Tyr Cys Gly1 5 1036313PRTArtificial Sequenceisolated from phage display libraries 363Tyr Trp Trp Glu Gln Trp Tyr Ser Trp Trp Ile Glu His1 5 1036413PRTArtificial Sequenceisolated from phage display libraries 364Tyr Tyr Arg Asp Ala Ser Tyr Thr Tyr Pro Tyr Met Tyr1 5 1036513PRTArtificial Sequenceisolated from phage display libraries 365Tyr Tyr Tyr Ile Pro Val Tyr Ser Ala Gln Cys Tyr Thr1 5 1036613PRTArtificial Sequenceisolated from phage display libraries 366Ala Cys Pro Trp Pro Ile Pro Pro Trp Pro Leu Arg Val1 5 1036713PRTArtificial Sequenceisolated from phage display libraries 367Ala Arg Arg Trp Pro Leu Pro Arg Arg Asp Gln Phe Ser1 5 1036813PRTArtificial Sequenceisolated from phage display libraries 368Cys Arg Arg Ile Gln Gln Pro Cys Val Phe Arg Arg His1 5 1036913PRTArtificial Sequenceisolated from phage display libraries 369Asp Glu Pro Pro Cys Ala Pro Glu Cys Asn Gly Asp Gly1 5 1037013PRTArtificial Sequenceisolated from phage display libraries 370Asp Phe Gln Phe Pro Lys Pro Ala Phe Cys Ser Thr Cys1 5 1037113PRTArtificial Sequenceisolated from phage display libraries 371Glu Leu Tyr Phe Phe Phe Pro Cys Gly Ser Phe Cys Gln1 5 1037213PRTArtificial Sequenceisolated from phage display libraries 372Phe Phe Gly Phe Asn His Pro Phe Leu Phe Ser

Cys Trp1 5 1037313PRTArtificial Sequenceisolated from phage display libraries 373Phe Phe Gln Ser Ile Gln Pro Ile Phe Ala Arg Ser Met1 5 1037413PRTArtificial Sequenceisolated from phage display libraries 374Phe Phe Trp Val Lys Asp Pro Ser Pro Cys Phe Asp His1 5 1037513PRTArtificial Sequenceisolated from phage display libraries 375Phe Gly Lys Phe Phe Asp Pro Leu Arg Arg Ala Lys Asp1 5 1037613PRTArtificial Sequenceisolated from phage display libraries 376Phe Lys Gly Glu Phe Trp Pro Ala Phe Gly Val Gln Val1 5 1037713PRTArtificial Sequenceisolated from phage display libraries 377Phe Lys Leu His Trp Phe Pro Thr Cys Pro Phe Ile Gln1 5 1037813PRTArtificial Sequenceisolated from phage display libraries 378Phe Leu Ser Phe Val Phe Pro Ala Ser Ala Trp Gly Gly1 5 1037913PRTArtificial Sequenceisolated from phage display libraries 379Phe Met Asp Ile Trp Ser Pro Trp His Leu Leu Gly Thr1 5 1038013PRTArtificial Sequenceisolated from phage display libraries 380Phe Asn Pro Pro Glu Pro Pro Cys Pro Glu Phe Ser Lys1 5 1038113PRTArtificial Sequenceisolated from phage display libraries 381Phe Gln Phe Phe Asp Pro Pro Ser Phe Phe Gly Phe Lys1 5 1038213PRTArtificial Sequenceisolated from phage display libraries 382Phe Gln Phe Ser Phe Gln Pro Asp Gly Val Glu Arg Arg1 5 1038313PRTArtificial Sequenceisolated from phage display libraries 383Phe Gln Asn Cys Phe Trp Pro Ile Phe Glu Ala Met Glu1 5 1038413PRTArtificial Sequenceisolated from phage display libraries 384Phe Ser Phe Phe Ala Asp Pro Ile Glu Leu Glu Trp Asp1 5 1038512PRTArtificial Sequenceisolated from phage display libraries 385Phe Ser Ser Leu Phe Phe Pro His Trp Ala Gln Leu1 5 1038613PRTArtificial Sequenceisolated from phage display libraries 386Phe Tyr Met Pro Phe Gly Pro Thr Trp Trp Gln His Val1 5 1038713PRTArtificial Sequenceisolated from phage display libraries 387Phe Tyr Tyr Phe Gly Phe Pro Gln Cys Leu Ile Leu Phe1 5 1038813PRTArtificial Sequenceisolated from phage display libraries 388Gly Phe Glu Glu Phe Gln Pro Val Asp Phe Ile Ile Arg1 5 1038913PRTArtificial Sequenceisolated from phage display libraries 389Gly Leu Thr Arg Phe Phe Pro Val Ser Phe Ser Phe Phe1 5 1039013PRTArtificial Sequenceisolated from phage display libraries 390His Ala Arg Pro Pro Cys Pro Phe Val Asn Glu Lys Pro1 5 1039113PRTArtificial Sequenceisolated from phage display libraries 391His Glu Phe Met Trp Phe Pro Val His Trp Glu Phe His1 5 1039213PRTArtificial Sequenceisolated from phage display libraries 392His Arg Asn Pro Arg Arg Pro Gln Ile Glu Gly Val Arg1 5 1039313PRTArtificial Sequenceisolated from phage display libraries 393Ile Ser Gly His Cys Phe Pro Cys Ile Glu Val Ser Asp1 5 1039413PRTArtificial Sequenceisolated from phage display libraries 394Lys Phe Gln Asp Phe Met Pro Gln Met Phe His Gly Ile1 5 1039513PRTArtificial Sequenceisolated from phage display libraries 395Leu Phe Phe Met Pro Phe Pro Phe Phe Phe Phe Pro Tyr1 5 1039613PRTArtificial Sequenceisolated from phage display libraries 396Leu Phe Ser Trp Phe Leu Pro Thr Asp Asn Tyr Pro Val1 5 1039713PRTArtificial Sequenceisolated from phage display libraries 397Leu Val Cys Ile Arg Arg Pro Arg Arg Arg Cys Phe Cys1 5 1039813PRTArtificial Sequenceisolated from phage display libraries 398Met Pro Arg Arg Glu Arg Pro Leu Trp Met Leu Thr Arg1 5 1039913PRTArtificial Sequenceisolated from phage display libraries 399Met Arg Arg His Arg Ala Pro Arg Ser Gln Cys Met Glu1 5 1040013PRTArtificial Sequenceisolated from phage display libraries 400Asn Phe Phe Gly Pro Ile Pro Met Asn Phe Ala Phe Thr1 5 1040113PRTArtificial Sequenceisolated from phage display libraries 401Asn Phe Phe Ser Ile Asp Pro Phe Cys Gln Ala Ile Tyr1 5 1040213PRTArtificial Sequenceisolated from phage display libraries 402Asn Asn Gly Ala Arg Arg Pro Tyr Val Ala Ser Asn Pro1 5 1040313PRTArtificial Sequenceisolated from phage display libraries 403Asn Arg Arg Arg Tyr Arg Pro Arg Phe Tyr Arg Arg Cys1 5 1040413PRTArtificial Sequenceisolated from phage display libraries 404Pro Phe Phe Trp Met Phe Pro Ile Cys Phe Pro Pro Asn1 5 1040513PRTArtificial Sequenceisolated from phage display libraries 405Pro Phe Gly Leu Phe Pro Pro Gln Val Tyr Tyr Phe Leu1 5 1040613PRTArtificial Sequenceisolated from phage display libraries 406Pro Gly Ala Ala Pro Pro Pro Cys Asn Asn Ser Asp Asn1 5 1040713PRTArtificial Sequenceisolated from phage display libraries 407Pro Pro Cys Pro Trp Arg Pro Ser Ala Thr His Leu Pro1 5 1040813PRTArtificial Sequenceisolated from phage display libraries 408Pro Pro Lys Phe Leu Ala Pro His Thr Ser Ala Met Leu1 5 1040913PRTArtificial Sequenceisolated from phage display libraries 409Pro Pro Arg Val Ala Phe Pro Ile Arg Gln Arg Arg Val1 5 1041013PRTArtificial Sequenceisolated from phage display libraries 410Pro Thr Arg Pro Asn Gly Pro Glu Ser Glu Asp Leu Phe1 5 1041113PRTArtificial Sequenceisolated from phage display libraries 411Gln Cys Pro Asp Pro Ser Pro Ser Lys Cys Pro Phe Gly1 5 1041213PRTArtificial Sequenceisolated from phage display libraries 412Gln Arg Arg Ala Pro Arg Pro Ser Glu His Arg Arg Glu1 5 1041313PRTArtificial Sequenceisolated from phage display libraries 413Arg Ala Arg Arg Ala Gly Pro Leu Gly Asp Arg Lys Leu1 5 1041413PRTArtificial Sequenceisolated from phage display libraries 414Arg Glu Gly Arg Thr Arg Pro Arg Tyr Pro Arg Trp Phe1 5 1041513PRTArtificial Sequenceisolated from phage display libraries 415Arg Glu Pro Asn Pro Pro Pro Leu Gln Ser Pro Met Ser1 5 1041613PRTArtificial Sequenceisolated from phage display libraries 416Arg Gly Phe Gln Phe Gly Pro Ser Thr Phe Glu Tyr Phe1 5 1041713PRTArtificial Sequenceisolated from phage display libraries 417Arg Gly Pro Arg Arg Thr Pro Thr Ile His Arg Pro Trp1 5 1041813PRTArtificial Sequenceisolated from phage display libraries 418Arg His Phe His Val Arg Pro Val Asn Trp Trp Ser Lys1 5 1041913PRTArtificial Sequenceisolated from phage display libraries 419Arg Ile Asn Arg Ser Arg Pro Ile Met Trp Gln Arg Thr1 5 1042013PRTArtificial Sequenceisolated from phage display libraries 420Arg Asn Asp Arg Val Arg Pro Trp Lys Val Lys His Gln1 5 1042113PRTArtificial Sequenceisolated from phage display libraries 421Arg Asn Met Arg Tyr Arg Pro Gln Tyr Ala Asp Leu Cys1 5 1042213PRTArtificial Sequenceisolated from phage display libraries 422Arg Asn Asn Arg Pro Lys Pro Thr Gln Ser His Arg Val1 5 1042313PRTArtificial Sequenceisolated from phage display libraries 423Arg Arg His Arg Trp Trp Pro Gln Glu Phe Ser Arg His1 5 1042413PRTArtificial Sequenceisolated from phage display libraries 424Arg Arg Arg Leu Phe Thr Pro Asn Ser Arg Ala Arg His1 5 1042513PRTArtificial Sequenceisolated from phage display libraries 425Arg Arg Ser Arg Phe Val Pro Glu Tyr Leu Phe Arg Pro1 5 1042613PRTArtificial Sequenceisolated from phage display libraries 426Arg Trp His Pro Arg Tyr Pro Val Met Lys Lys Asn Ser1 5 1042713PRTArtificial Sequenceisolated from phage display libraries 427Arg Trp Ile Pro Arg Pro Pro Arg Arg Ala Cys Arg Arg1 5 1042813PRTArtificial Sequenceisolated from phage display libraries 428Ser Phe Trp Pro Phe Cys Pro Thr Thr Trp Ala Asn Tyr1 5 1042913PRTArtificial Sequenceisolated from phage display libraries 429Ser Ile Phe Gln Phe Asn Pro Phe Pro Glu Gly Phe Phe1 5 1043013PRTArtificial Sequenceisolated from phage display libraries 430Ser Leu Phe Phe Met Pro Pro Glu Arg Leu Asp His Arg1 5 1043113PRTArtificial Sequenceisolated from phage display libraries 431Ser Asn Arg His Arg Arg Pro Arg Arg Arg Trp Arg Met1 5 1043213PRTArtificial Sequenceisolated from phage display libraries 432Thr Phe Phe Thr Asn Lys Pro Phe Ser Tyr His Phe Glu1 5 1043313PRTArtificial Sequenceisolated from phage display libraries 433Thr Thr Pro Val Gln Pro Pro Gly Glu Val Ser Gln Val1 5 1043413PRTArtificial Sequenceisolated from phage display libraries 434Thr Tyr Asn Ser Phe Phe Pro Phe Arg His Phe Ala Glu1 5 1043513PRTArtificial Sequenceisolated from phage display libraries 435Val Lys Ile Arg Arg Arg Pro Arg Arg Met Arg Leu Met1 5 1043613PRTArtificial Sequenceisolated from phage display libraries 436Trp Lys His Pro Pro Arg Pro Tyr Cys Trp Lys Pro Leu1 5 1043713PRTArtificial Sequenceisolated from phage display libraries 437Tyr Ile Tyr Thr Val Tyr Pro Arg Asn Ser Ser Trp Phe1 5 1043813PRTArtificial Sequenceisolated from phage display libraries 438Tyr Gln Pro Trp Gly Pro Pro Pro Pro Pro Leu Val Leu1 5 1043913PRTArtificial Sequenceisolated from phage display libraries 439Ala Arg Asp Tyr Asp Asn Asn Met Lys Tyr Tyr Leu Asp1 5 1044013PRTArtificial Sequenceisolated from phage display libraries 440Ala Arg Ile Asn Asn Lys Asn Val Ile Thr Phe Gln Pro1 5 1044113PRTArtificial Sequenceisolated from phage display libraries 441Ala Ser Arg Ser Ser Asp Asn Ile Ser Tyr Ser Ser Thr1 5 1044213PRTArtificial Sequenceisolated from phage display libraries 442Ala Ser Ser Asp Ala Gly Asn Tyr Glu Ile Ala Gly Pro1 5 1044313PRTArtificial Sequenceisolated from phage display libraries 443Ala Thr Asp Asp Glu Asn Asn Glu Met Asn Val Gly Met1 5 1044413PRTArtificial Sequenceisolated from phage display libraries 444Cys Ser Ser Phe Ser Leu Asn Trp Ser Leu Ser Lys Ser1 5 1044513PRTArtificial Sequenceisolated from phage display libraries 445Asp Cys Asp His Leu Phe Asn Met Glu Gln Thr Leu Arg1 5 1044613PRTArtificial Sequenceisolated from phage display libraries 446Asp Cys Val Ser Ser Asn Asn His Asp Ile Thr Arg Gly1 5 1044713PRTArtificial Sequenceisolated from phage display libraries 447Asp Asp Glu Arg Val Ile Asn Ser Asp Tyr Ser Glu Tyr1 5 1044813PRTArtificial Sequenceisolated from phage display libraries 448Asp Asp Lys Asn Glu Asp Asn Asp Ile Pro Lys Thr Pro1 5 1044913PRTArtificial Sequenceisolated from phage display libraries 449Asp Asp Thr Asn Asp Met Asn Asn Ser Glu Glu Lys Phe1 5 1045013PRTArtificial Sequenceisolated from phage display libraries 450Asp Asp Val Gln Asp Asp Asn Asp Gln Pro Tyr Asn Thr1 5 1045113PRTArtificial Sequenceisolated from phage display libraries 451Asp Lys Gly Asn Asp Gln Asn Asn Ser Pro Leu Trp Ala1 5 1045213PRTArtificial Sequenceisolated from phage display libraries 452Asp Leu Val Cys Asn Asn Asn Cys Arg Asn Leu Phe Asn1 5 1045313PRTArtificial Sequenceisolated from phage display libraries 453Asp Asn His Asp Lys Phe Asn Gln Ala Ile Gln Asp Trp1 5 1045413PRTArtificial Sequenceisolated from phage display libraries 454Asp Arg Cys Asn Gly Asp Asn Trp Cys Asn Gln Gly Asp1 5 1045513PRTArtificial Sequenceisolated from phage display libraries 455Asp Ser Glu Tyr Leu Ser Asn Lys Ser Val Asn Asp Phe1 5 1045613PRTArtificial Sequenceisolated from phage display libraries 456Asp Thr Met Thr Asp Asn Asn Gln Gly Asp Asp Gln Trp1 5 1045713PRTArtificial Sequenceisolated from phage display libraries 457Glu Lys Asn Trp Asn Tyr Asn Pro Val Met Leu Ala Asn1 5 1045813PRTArtificial Sequenceisolated from phage display libraries 458Phe Phe Ser Phe Leu Pro Asn Ser Asp Arg Phe Gln Trp1 5 1045913PRTArtificial Sequenceisolated from phage display libraries 459Phe Phe Ser Tyr Trp Ser Asn Phe Asp Ala Ser Trp His1 5 1046013PRTArtificial Sequenceisolated from phage display libraries 460Phe His Ile Asp Asp Asp Asn Asp Phe Asp Thr Thr Ser1 5 1046113PRTArtificial Sequenceisolated from phage display libraries 461Phe Asn Asn Phe Asn Asp Asn Glu His Asn Val Asn Lys1 5 1046213PRTArtificial Sequenceisolated from phage display libraries 462Phe Tyr Asn Ile Val Asn Asn Ile Phe Ile Cys Cys Ile1 5 1046313PRTArtificial Sequenceisolated from phage display libraries 463Phe Tyr Trp Asp Arg Leu Asn Val Gly Trp Gly Leu Leu1 5 1046413PRTArtificial Sequenceisolated from phage display libraries 464Gly Asp Asn His Asn His Asn Thr Asn Thr Ile Glu Pro1 5 1046513PRTArtificial Sequenceisolated from phage display libraries 465His Ala Asp Gln Asp Asp Asn Cys Arg Gly Lys Asp Asp1 5 1046613PRTArtificial Sequenceisolated from phage display libraries 466His Asp Trp Asp Asp Trp Asn Ile Glu Ala Glu Asp Gly1 5 1046713PRTArtificial Sequenceisolated from phage display libraries 467His Gly Ser Ser Asp Thr Asn Gly Gln Ile Leu Phe Glu1 5 1046813PRTArtificial Sequenceisolated from phage display libraries 468His Asn Trp Asn His Asn Asn Asn Leu Ile Asp Arg Phe1 5 1046913PRTArtificial Sequenceisolated from phage display libraries 469Ile Cys Asp Asp Asp Asn Asn Met His Leu Tyr Glu Pro1 5 1047013PRTArtificial Sequenceisolated from phage display libraries 470Ile Asp Asp Ser His Leu Asn Asp Gln Cys Arg Asp Asp1 5 1047113PRTArtificial Sequenceisolated from phage display libraries 471Ile Asn Cys Asn Asn Asn Asn Ser Leu Asn Asn Asn Asn1 5 1047213PRTArtificial Sequenceisolated from phage display libraries 472Ile Asn Asn Val Val Tyr Asn Leu His Asp Arg Asn Asn1 5 1047313PRTArtificial Sequenceisolated from phage display libraries 473Ile Ser Asn Cys Asn Ile Asn Asn Gly Asn Asn Asp Ser1 5 1047413PRTArtificial Sequenceisolated from phage display libraries 474Ile Ser Asn Arg Gln Ser Asn Thr Ser Asn Gly Met Ser1 5 1047513PRTArtificial Sequenceisolated from phage display libraries 475Lys Phe Ser Ser Leu His Asn Ile Ser Gly Pro Lys Ser1 5 1047613PRTArtificial Sequenceisolated from phage display libraries 476Lys Asn Leu Asn Gln Asn Asn Asn Asn His Phe Asn Asn1 5 1047713PRTArtificial Sequenceisolated from phage display libraries 477Lys Asn Arg Val Asn Lys Asn Thr Asn Val His Cys Phe1 5 1047813PRTArtificial Sequenceisolated from phage display libraries 478Leu Ser Asn Leu Asn Tyr Asn Pro Asn His His Asp Met1 5 1047913PRTArtificial Sequenceisolated from phage display libraries 479Met Arg Ser Ser Ser Phe Asn Phe Gly Ser Phe Asp Gln1 5 1048013PRTArtificial Sequenceisolated from phage display libraries 480Met Ser Asn Ser Ser Ser Asn Ser Ser Ser Ser Ser Gly1 5 1048113PRTArtificial Sequenceisolated from phage display libraries 481Met Tyr Ser Asn Tyr Tyr Asn Phe Leu Gln Lys Ser Trp1 5 1048213PRTArtificial Sequenceisolated from phage display libraries 482Asn Asp Arg Asn Asp His Asn Gln His Arg Tyr Asp His1 5 1048313PRTArtificial Sequenceisolated from phage display libraries 483Asn Glu Met Trp Asn Asn Asn Asn Val Met Asn His His1 5 1048413PRTArtificial Sequenceisolated from

phage display libraries 484Asn Glu Asn Glu Asn Asp Asn Asn Met Asn Met Glu Ile1 5 1048513PRTArtificial Sequenceisolated from phage display libraries 485Asn Asn Asn Ser Asn His Asn Asp Pro Thr Asn Ala Glu1 5 1048613PRTArtificial Sequenceisolated from phage display libraries 486Asn Asn Val Leu Asn His Asn Cys Asn Met Phe Leu Asn1 5 1048713PRTArtificial Sequenceisolated from phage display libraries 487Asn Pro Thr Lys Asn Arg Asn Thr His Leu Gly Gly Arg1 5 1048813PRTArtificial Sequenceisolated from phage display libraries 488Asn Arg Glu Val Lys Asn Asn Arg Gln Lys Val Phe Lys1 5 1048913PRTArtificial Sequenceisolated from phage display libraries 489Asn Arg Asn Asn His Phe Asn Asn Glu Tyr Glu Trp Asn1 5 1049013PRTArtificial Sequenceisolated from phage display libraries 490Asn Thr Asp Leu Asn Asn Asn Gln Thr Val Ser Asn Arg1 5 1049113PRTArtificial Sequenceisolated from phage display libraries 491Pro Asp Asp Ala Pro His Asn Tyr Cys Thr Asp Pro Leu1 5 1049213PRTArtificial Sequenceisolated from phage display libraries 492Pro Lys Asp Asp Arg Asn Asn Thr Val Ala Ser Cys Glu1 5 1049313PRTArtificial Sequenceisolated from phage display libraries 493Pro Val Asn Tyr Ala Asn Asn Pro Glu Arg Val Gly His1 5 1049413PRTArtificial Sequenceisolated from phage display libraries 494Pro Tyr Asn Gly Ser Asn Asn Asn Asn Ala Thr Val Pro1 5 1049513PRTArtificial Sequenceisolated from phage display libraries 495Gln Asn Ser Gln His Asn Asn His His Cys Val Leu Gly1 5 1049613PRTArtificial Sequenceisolated from phage display libraries 496Arg Ser Ser Ser Ser Gly Asn Ser Ser His His His Met1 5 1049713PRTArtificial Sequenceisolated from phage display libraries 497Ser Glu Ser Asn Ser Asn Asn Pro Gly His Asn Leu Pro1 5 1049813PRTArtificial Sequenceisolated from phage display libraries 498Ser Phe Leu Asn Asn Cys Asn His Asn Lys Leu Met Ser1 5 1049913PRTArtificial Sequenceisolated from phage display libraries 499Ser Ile Phe Asn Ser Ser Asn His Thr His Gln Ser Met1 5 1050013PRTArtificial Sequenceisolated from phage display libraries 500Ser Asn Met Asp Ser Ser Asn Ala Pro Gln Ser Trp Val1 5 1050113PRTArtificial Sequenceisolated from phage display libraries 501Ser Asn Ser Trp Asn Asn Asn Glu Asp Lys His Ile Leu1 5 1050213PRTArtificial Sequenceisolated from phage display libraries 502Ser Arg Ser Gly Trp Ser Asn Tyr Phe Cys Ser Arg Gln1 5 1050313PRTArtificial Sequenceisolated from phage display libraries 503Ser Ser Met Leu His Asn Asn Pro Trp Ser Lys Trp Ser1 5 1050413PRTArtificial Sequenceisolated from phage display libraries 504Ser Ser Asn Gln Val Ile Asn Thr Phe Glu Asp Leu Gln1 5 1050513PRTArtificial Sequenceisolated from phage display libraries 505Ser Ser Gln Ser Met Pro Asn Gly Ser Gly Lys Glu Thr1 5 1050613PRTArtificial Sequenceisolated from phage display libraries 506Ser Val Ser Cys Ser Cys Asn Thr Ser Arg Gly Cys Ser1 5 1050713PRTArtificial Sequenceisolated from phage display libraries 507Ser Val Ser Ser Lys Ser Asn Glu Ile Ser Phe Cys Thr1 5 1050813PRTArtificial Sequenceisolated from phage display libraries 508Thr Asp Ser Gly Ser Ser Asn Ser Ala Lys Ala Ile Cys1 5 1050913PRTArtificial Sequenceisolated from phage display libraries 509Thr Asn Trp Cys Ser Ser Asn Val Gly Ser Asn Thr Ser1 5 1051013PRTArtificial Sequenceisolated from phage display libraries 510Thr Ser Ser Trp Ser Phe Asn Gly Thr Asn Gly Ser Ala1 5 1051113PRTArtificial Sequenceisolated from phage display libraries 511Val Ala Asp Ser Phe Asp Asn Ala Asn Tyr Thr Leu Asp1 5 1051213PRTArtificial Sequenceisolated from phage display libraries 512Val Asp Asp Gln Tyr Asp Asn Trp Asp Ile Arg Asp Cys1 5 1051313PRTArtificial Sequenceisolated from phage display libraries 513Tyr Asn Gly Asn Tyr His Asn His Gly Leu Asn Ile Arg1 5 1051413PRTArtificial Sequenceisolated from phage display libraries 514Cys Phe Val Leu Asn Cys His Leu Val Leu Asp Arg Pro1 5 1051513PRTArtificial Sequenceisolated from phage display libraries 515Cys Arg Arg Pro Phe Glu His Ala Leu Phe Tyr Ala Ser1 5 1051613PRTArtificial Sequenceisolated from phage display libraries 516Asp Ser Trp Leu Leu Ser His Ser Arg Ser Lys Ser Met1 5 1051713PRTArtificial Sequenceisolated from phage display libraries 517Asp Ser Trp Trp Thr Gln His Ser Gln Ala His Ser Asp1 5 1051813PRTArtificial Sequenceisolated from phage display libraries 518Asp Thr Asn Met Leu Asn His Gly Met Tyr Gly His Cys1 5 1051913PRTArtificial Sequenceisolated from phage display libraries 519Glu Asn Ile Asn Ala Ser His Cys Leu Ser Thr Val Asp1 5 1052013PRTArtificial Sequenceisolated from phage display libraries 520Phe Phe Ser Tyr Ser Gly His Leu Val Gln Lys Val Trp1 5 1052113PRTArtificial Sequenceisolated from phage display libraries 521Phe Met Phe Ala Val Trp His Asp Gly His Ile Lys Asn1 5 1052213PRTArtificial Sequenceisolated from phage display libraries 522Phe Met Ser Gln His Phe His Asn Pro Met Met Ile Arg1 5 1052313PRTArtificial Sequenceisolated from phage display libraries 523Phe Val Phe Tyr Ile Met His Tyr Cys Gly His Phe Met1 5 1052413PRTArtificial Sequenceisolated from phage display libraries 524His Phe Lys Asp Asp Asp His Met Met Leu Tyr Gly Pro1 5 1052513PRTArtificial Sequenceisolated from phage display libraries 525His Thr Gln His Arg Leu His Val Gly Gln Ser Ser Ser1 5 1052613PRTArtificial Sequenceisolated from phage display libraries 526Ile Ser Asn Ser Trp Tyr His Trp Ser Trp Glu Met Trp1 5 1052713PRTArtificial Sequenceisolated from phage display libraries 527Leu Cys Phe Tyr Glu Tyr His Phe Met Gln Cys Ala Met1 5 1052813PRTArtificial Sequenceisolated from phage display libraries 528Leu Gly Leu Ser Asp Ser His Tyr Glu Cys Ser Phe Arg1 5 1052913PRTArtificial Sequenceisolated from phage display libraries 529Leu Arg Ser Thr Ser Phe His Phe Arg Cys Ala Lys Cys1 5 1053013PRTArtificial Sequenceisolated from phage display libraries 530Leu Ser Val Phe Ser His His Lys Trp Val Tyr Thr Ser1 5 1053113PRTArtificial Sequenceisolated from phage display libraries 531Met Ala Met His His Met His His Met Ala Asn Asn Leu1 5 1053213PRTArtificial Sequenceisolated from phage display libraries 532Met Ser Ser Phe Asp Val His Arg Ser His Thr Asn Ser1 5 1053313PRTArtificial Sequenceisolated from phage display libraries 533Pro Gly Ser Leu Ser Glu His Ile Tyr Gln Ala Trp Ser1 5 1053413PRTArtificial Sequenceisolated from phage display libraries 534Pro Ser Ser Ala Ser Met His Ile Ala Ser Ser Cys Ile1 5 1053513PRTArtificial Sequenceisolated from phage display libraries 535Gln Tyr Trp Trp Ile Trp His Lys Ser Asp Ser Gly Ser1 5 1053613PRTArtificial Sequenceisolated from phage display libraries 536Ser Gly Gln Ser Asn Ser His His Asp Lys Thr Ile Cys1 5 1053713PRTArtificial Sequenceisolated from phage display libraries 537Ser Gly Gln Ser Val Phe His His Phe Phe Pro Asn Asp1 5 1053813PRTArtificial Sequenceisolated from phage display libraries 538Ser His Val Ser Leu Tyr His Ala Ser Thr Asp Ser Asp1 5 1053913PRTArtificial Sequenceisolated from phage display libraries 539Ser Met Ser Ser Ser Lys His Met Asp Met Asp Cys Phe1 5 1054013PRTArtificial Sequenceisolated from phage display libraries 540Ser Ser Cys Leu Pro Ser His Val Arg Ser Asp Thr Lys1 5 1054113PRTArtificial Sequenceisolated from phage display libraries 541Ser Ser Gly Met Ser Glu His Thr Pro Leu Cys Ser Glu1 5 1054213PRTArtificial Sequenceisolated from phage display libraries 542Ser Ser Pro Ser Phe Pro His Met Trp Ser Glu Asp Glu1 5 1054313PRTArtificial Sequenceisolated from phage display libraries 543Val His Ser Glu Ser Trp His Ser Tyr Ser Ile His Ala1 5 1054413PRTArtificial Sequenceisolated from phage display libraries 544Val Asn Asn Ala Met Gly His Met Gly Met Met Trp Cys1 5 1054513PRTArtificial Sequenceisolated from phage display libraries 545Val Ser Cys Ser Ser Arg His Tyr Ser Ile Ser Trp Ser1 5 1054613PRTArtificial Sequenceisolated from phage display libraries 546Trp Thr Trp Lys Arg Gln His His Arg Ser Ser Leu Tyr1 5 1054713PRTArtificial Sequenceisolated from phage display libraries 547Tyr Ile Ser Phe Phe Glu His Gly Gln Ile Val Asp Ser1 5 1054819PRTArtificial Sequenceisolated from phage display libraries 548Ser Cys Leu Val Phe Met Arg Pro Tyr Phe Leu Leu Val Phe Leu Met1 5 10 15Cys Trp Ser54919PRTArtificial Sequenceisolated from phage display libraries 549Ser Cys Thr Phe Gly Phe Pro Cys Val Met Ser Leu Val Asn His Val1 5 10 15Pro Ser Ser55019PRTArtificial Sequenceisolated from phage display libraries 550Ser Cys Leu Tyr Cys Leu Asn Tyr Ala Asn Phe Ser Asp Pro Met Thr1 5 10 15Met Phe Ser55113PRTArtificial Sequenceisolated from phage display libraries 551Gly Phe Ala Trp Ser Ser Tyr Leu Gly Thr Thr Val His1 5 1055213PRTArtificial Sequenceisolated from phage display libraries 552Leu Phe Gly Pro Ile Glu Tyr Thr Gln Phe Leu Ala Asn1 5 1055313PRTArtificial Sequenceisolated from phage display libraries 553Phe Phe Ser Phe Phe Phe Pro Ala Ser Ala Trp Gly Ser1 5 1055420PRTArtificial Sequenceisolated from phage display libraries 554Phe Phe Ser Phe Phe Phe Pro Ala Ser Ala Trp Gly Ser Ser Gly Ser1 5 10 15Ser Arg Gly Asp 2055512PRTArtificial Sequenceisolated from phage display libraries 555Leu Leu Ser Leu Leu Leu Pro Gly Ser Ser Gly Lys1 5 1055612PRTArtificial Sequenceisolated from phage display libraries 556Ile Ile Ser Ile Ile Ile Pro Gly Ser Ser Gly Lys1 5 1055712PRTArtificial Sequenceisolated from phage display libraries 557Phe Trp Ser Phe Trp Phe Pro Gly Ser Ser Gly Lys1 5 1055832PRTArtificial Sequenceisolated from phage display libraries 558Ser Cys Ser Asp Cys Leu Lys Ser Val Asp Phe Ile Pro Ser Ser Leu1 5 10 15Ala Ser Ser Ser Ser Gly Arg Gly Asp Ser Pro Gly Arg Gly Asp Ser 20 25 30

* * * * *